Mathematical modeling of diseases to inform health policy by Faissol, Daniel Mello








of the Requirements for the Degree
Doctor of Philosophy in the
H. Milton Stewart School of Industrial and Systems Engineering
Georgia Institute of Technology
Aug 2008




Division of STD Prevention
Centers for Disease Control and Pre-
vention
Pinar Keskinocak
H. Milton Stewart School of Industrial
and Systems Engineering
Georgia Institute of Technology
David M. Goldsman
H. Milton Stewart School of Industrial
and Systems Engineering
Georgia Institute of Technology
Julie L. Swann
H. Milton Stewart School of Industrial
and Systems Engineering
Georgia Institute of Technology
Paul M. Griffin
H. Milton Stewart School of Industrial
and Systems Engineering
Georgia Institute of Technology
Date Approved: Aug 2008
To my father,
Sergio Zarur Faissol,
whose inspiration made this possible.
iii
ACKNOWLEDGEMENTS
I would like to thank many people for their contributions that led to this dissertation.
I would first like to thank my advisors, Julie Swann and Paul Griffin, with whom I
had the very good fortune of working. I am grateful for the generous amount of time
and effort they both contributed. I consider myself to be one of the more fortunate
students for having advisors of such good nature and genuine interest in my success
as a graduate student and beyond.
I would like to thank the other members of my committee, especially Thomas
Gift who collaborated with us on Chapter 2, as well as David Goldsman and Pinar
Keskinocak for their helpful comments and patience. Additionally, I would like to
express my gratitude to many of the ISyE faculty and staff, several of whom went
well beyond the call of duty, particularly Steven Hackman for his entertaining classes
from which I learned a great deal.
I am also very grateful for the financial support that the AT&T Labs Fellowship
Program and the NASA Harriet G. Jenkins Predoctoral Fellowship Program have
provided me during my time as a graduate student.
I have had the pleasure of knowing and working with many fellow graduate stu-
dents of whom there are too many to list. I would however, like to thank H. Eser
Kirkizlar for his collaboration in Chapter 3, Claudio Santiago and Helder Inacio for
their help in Chapter 5, Charles Leslie Wardell for allowing me to carry him on my
shoulders during our course work and as we prepared for the comprehensive exam, and
each of them for their invaluable friendship and support during my entire graduate
career.
Finally, I would like to thank my family: Sergio, Mirian, Cecilia and Patricia
iv
Faissol, in decreasing order of very old age. My parents’ hard work, dedication,
patience, support and love are more than anybody could ever ask for, without which
I would not have even begun writing this document. Lastly, I owe a special debt
of gratitude to my fiancée, Dorothy, who is arguably my better half. Her patience,




DEDICATION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . iii
ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . iv
LIST OF TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . viii
LIST OF FIGURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ix
I INTRODUCTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
II A BERNOULLI PROCESS TRANSMISSION MODEL FOR HIV TRANS-
MISSION: THE ROLE OF BATHHOUSES IN HIV TRANSMISSION . 4
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
2.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
2.2.1 The Mathematical Model . . . . . . . . . . . . . . . . . . . 6
2.2.2 Including Syphilis . . . . . . . . . . . . . . . . . . . . . . . 11
2.2.3 Analytics . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
2.2.4 Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
2.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
2.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
2.5 Appendix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
III TIMING OF TESTING AND TREATMENT FOR ASYMPTOMATIC DIS-
EASES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
3.1 Introduction1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
3.2 Literature . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
3.3 Model and Structural Results . . . . . . . . . . . . . . . . . . . . . 36
3.3.1 The Mathematical Model . . . . . . . . . . . . . . . . . . . 36
3.4 Application of the Model to HCV . . . . . . . . . . . . . . . . . . . 42
3.5 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
3.6 Appendix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
1This chapter is a collaborative effort with H. Eser Kirkizlar.
vi
IV TESTING FOR HEPATITIS C VIRUS: IMPLICATIONS FOR POLICY 53
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
4.2 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . 54
4.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
4.3.1 Overall Population . . . . . . . . . . . . . . . . . . . . . . . 57
4.3.2 At Risk Populations . . . . . . . . . . . . . . . . . . . . . . 60
4.4 Sensitivity Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
4.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
V BIAS IN MARKOV MODELS OF DISEASES . . . . . . . . . . . . . . 70
5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
5.2 Markov Models of Various Diseases . . . . . . . . . . . . . . . . . . 71
5.3 Monte Carlo Simulations of Markov Models of Diseases . . . . . . . 76
5.4 Stationary Distributions . . . . . . . . . . . . . . . . . . . . . . . . 78
5.4.1 State dependent transition probabilities . . . . . . . . . . . 78
5.4.2 Time dependent transition probabilities . . . . . . . . . . . 81
5.5 Analysis of Bias . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
5.5.1 Conditions for the existence of model bias . . . . . . . . . . 82
5.5.2 Factors that affect the degree of model bias . . . . . . . . . 87
5.6 Bias in Models of Hepatitis C, Alzheimer’s Disease and Lung Cancer 89
5.6.1 Bias in diseases with state dependent transition probabilities:
Hepatitis C and Alzheimer’s Disease . . . . . . . . . . . . . 89
5.6.2 Bias in diseases with time/age dependent transition proba-
bilities: Hepatitis C and Alzheimer’s Disease and Lung Cancer 91
5.7 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
5.8 Appendix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
VI CONCLUSIONS AND FUTURE RESEARCH DIRECTIONS . . . . . . 110
REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
VITA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
vii
LIST OF TABLES
1 Summary of data from the 1997 Urban Men’s Health Study. Any
differences in values shown are significant at the 0.05 level. . . . . . . 15
2 Epidemiologic variables used for base case and sensitivity analysis
along with corresponding references. . . . . . . . . . . . . . . . . . . . 17
3 Annual attack rate for different parameter values. The base case cor-
responds to the values reported in Table 2. . . . . . . . . . . . . . . . 22
4 Parameter values for model . . . . . . . . . . . . . . . . . . . . . . . 45
5 Results for the overall and IDU populations from implementing the
dynamic testing policy (standard errors are shown in parenthesis) . . 48
6 Parameter values for transition probabilities (reported in annual terms) 57
7 QALY values for various health states . . . . . . . . . . . . . . . . . . 58
8 Annual probability of HCV infection by type of risk group . . . . . . 58
9 Costs and discount value (where costs are in 2000 dollars) . . . . . . 59
10 Genotype, testing, and infection values . . . . . . . . . . . . . . . . . 59
11 Incrementally cost-effective two test policies for testing the overall pop-
ulation for HCV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
12 Multiple tests per lifetime for testing the overall on IDU populations
for HCV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
13 Results for testing various groups at risk for HCV. CSW = Commercial
Sex Workers. CE = cost-effectiveness. . . . . . . . . . . . . . . . . . 68
14 Sensitivity analysis for testing the overall population for HCV. CE =
cost-effective . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
15 Parameter values for transition probabilities . . . . . . . . . . . . . . 90
16 Results for HCV and AD with state dependent transition probabilities
for multiple degrees of data aggregation . . . . . . . . . . . . . . . . . 92
17 Liver Fibrosis estimates for HCV model. Source [57] . . . . . . . . . 92
18 Incidence of AD. Source [93] . . . . . . . . . . . . . . . . . . . . . . . 93
19 Results for HCV and AD with time dependent transition probabilities 94
20 Results for Lung Cancer with time dependent transition probabilities
for multiple degrees of data aggregation (smoking 20 cigarettes/day
since 15 years old) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
viii
LIST OF FIGURES
1 HIV attack rate as a function of zBH when the Bathhouse Patron Con-
dom Usage (BHP CU) is 75%, Non-bathhouse patron condom usage is
80%, overall syphilis prevalence is 0.5%, and the syphilis multiplier is 3. 18
2 HIV attack rate for varying levels of Bathhouse Patron Condom Usage
(BHP CU) and Bathhouse Patron Act Reduction due to bathhouse
closure (BHP AR), with other parameters set as in Figure 1. . . . . . 19
3 HIV attack rate for different Syphilis Prevalence (SP) and Syphilis
Multiplier Effect (SME) values, where Bathhouse patron condom usage
is 75% and Non-bathhouse patron condom usage is 80%. . . . . . . . 21
4 HIV attack rate for bathhouse closure as a function of the percentage
decrease in BH sexual activity within the bathhouse due to bathhouse
closure. BH condom usage is 75%, non-bathhouse condom usage is
80%, overall syphilis prevalence is 0.5%, and the syphilis multiplier
is 3. The horizontal dashed line is for the base case of keeping the
bathhouse open. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
5 Mean cost/QALY for the overall and IDU populations from implement-
ing the dynamic policy. Confidence intervals calculated using standard
errors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
6 The states of HCV where solid lines represent natural history transi-
tions and dashed lines represent transitions due to treatment success.
Not shown in the diagram but included in the model are transitions to
death from all states due to causes other than HCV. . . . . . . . . . . 55
7 Cost versus QALY for one test policies of the overall population under
various assumption. . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
8 Cost versus QALY for one and two test policies. . . . . . . . . . . . 61
9 Cost versus QALY of up to 5 tests per lifetime for the IDU population . 64
10 METAVIR standard for liver disease progression. . . . . . . . . . . . 71
11 Markov models for a disease with time dependent transition probabilities. 74
12 Markov model for a disease with state dependent transition probabili-
ties as used in Monte Carlo simulations. . . . . . . . . . . . . . . . . 76
13 Generalized Markov model of disease progression with state dependent
transition probabilities . . . . . . . . . . . . . . . . . . . . . . . . . . 79




Disease affects virtually everyone in society. Our increasing interconnectedness makes
understanding infectious diseases ever more critical. Coupled with the expanding
amount of health data currently available, the complex nature of many diseases make
them ideal candidates for mathematical modeling. In light of the rising costs of
health care, mathematical modeling provides a relatively inexpensive way of helping
us better understand how infectious diseases spread, how to better allocate funds,
and how to pick the most effective interventions aimed at preventing and treating
disease. In this dissertation we present mathematical models that help answer health
policy questions relating to HIV and Hepatitis C, and analyze bias in Markov models
of general disease progression.
In the next chapter, we study a specific question in HIV policy. During the initial
HIV outbreak in the 1980’s public health agencies around the country actively closed
down bathhouses because they were identified as a venue in which high risk behavior
was taking place and were perceived to be one of the major factors contributing to
the spread of HIV. Many of these venues have reopened today, and some blame them
for the increasing HIV incidence that is currently taking place. The debate as to how
public health agencies should react to this phenomenon lacked a mathematical anal-
ysis of the issue. To study the problem, we develop a Bernoulli process transmission
model where, for a given individual, each risky person-to-person contact is treated as
an independent Bernoulli trial with an associated probability of HIV transmission.
We extend the model to include a heterogeneous population with multiple risk groups
and add the effect of co-infection with other diseases, such as Syphilis, which increase
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the probability of transmission when present. We show that the HIV attack rate is
concave as a function of the proportion of the bathhouse patrons’ contacts that are
with other bathhouse patrons. We use this fact to draw conclusions on the effect of
closing bathhouses under certain assumptions.
We populate the model of HIV transmission with data from a survey of four
major cities in the US. A key finding is that the impact on HIV incidence from
the disproportionate mixing of the population due to the presence of bathhouses is
small compared to the impact from changes in some key parameter values, such as
condom usage. The effect that closing bathhouses will have on these parameter values
is not clear; however, the results suggest that alternative interventions targeted at
individuals in bathhouse venues could have greater effects on the spread of HIV than
closing bathhouses.
In Chapters 3 and 4, we build a mathematical model to examine the timing of
testing and treatment for diseases, particularly Hepatitis C. Hepatitis C is the lead-
ing cause for liver transplants and the 10th leading cause of death in US adults. It
is typically asymptomatic for decades yet still infectious during this period. Many
papers in the medical literature analyze the cost-effectiveness of screening by simu-
lating the disease and a limited number of a priori testing policies. However, this
may be insufficient to determine the best timing of the tests or incorporate changes
over time. In Chapters 3 and 4, we study this problem with a dual approach, both
analytical and simulation. We develop a Markov Decision Process (MDP) model for
diseases where our goal is to determine the best timing for testing (and treatment)
decisions when the presence of the disease is not known in advance; our model allows
for the awareness of a disease to change behavior.
Using medical data, we arrive at a dynamic policy of testing and treating for the
case of Hepatitis C in Chapter 3. In Chapter 4 we also simulate all policies of up to
five tests in a lifetime to examine both optimal and practically implementable policies.
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A key finding in both chapters is that the current policy recommendations on testing
for Hepatitis C are too restrictive, and that it is cost-effective to test the overall
population if done at the appropriate times. We also demonstrate the importance of
including behavior changes in the model and analyzing the optimal timing of tests
by comparing the results to previous studies.
The Markov models used in the study of Hepatitis C in Chapters 3 and 4 moti-
vated the topic in Chapter 5 where we examine bias in Markov models of diseases,
including the one studied in Chapter 3 and 4. We examine two classes of diseases
and the associated Markov models commonly used to model them: ones in which the
transition probabilities are state dependent (that is, they vary by severity of the dis-
ease), and ones in which the transition probabilities are time dependent. We find the
behavior of these Markov models in steady state and arrive at sufficient conditions
for bias to exist in models with aggregated transition probabilities when compared to
models with state/time dependent transition probabilities. We also find that when
aggregating data to compute transition probabilities, the bias increases with the de-
gree of data aggregation. We apply the results to Hepatitis C, Alzheimer’s disease
and lung cancer and find that the bias is significant depending on the method used
to aggregate the data.
In the final chapter we present possibilities for extensions of the research topics
discussed. We plan to expand the models in Chapters 3 and 5 to larger state spaces
so that we can model more complicated diseases. We aim to use the future results to
model diseases such as cancer, diabetes, and cardiovascular disease.
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CHAPTER II
A BERNOULLI PROCESS TRANSMISSION MODEL FOR
HIV TRANSMISSION: THE ROLE OF BATHHOUSES IN
HIV TRANSMISSION
2.1 Introduction
In the 1980s and early 1990s, sexually transmitted disease (STD) rates in men who
have sex with men (MSM) fell following the adoption of safer sex behavior among
those who were impacted most strongly in the early years of the HIV/AIDS epidemic
[49]. However, in the US, there continues to be a substantial amount of high risk
sexual behavior and HIV infection among MSM [15, 117, 17, 44, 30]. Although most
demographic categories have seen decreases in HIV incidence, MSM remain at high
risk and studies have shown increasing STD rates and risk behavior among MSM
[49, 27]. They make up approximately 45% of newly reported HIV/AIDS diagnoses
[18, 24] and annual incidence ranges from high levels of 1.2% to 8.0% [22]. In addition,
in several large US cities where approximately 25% of MSM have HIV, nearly 50%
are unaware of their infection [22].
Research has documented that commercial sex venues, such as bathhouses, pro-
vide opportunities for casual and anonymous sex between MSM [140, 129, 45, 134].
Bathhouses have been associated with behaviors that increase risk for STDs and HIV,
including sex with multiple partners and unprotected sex [129, 81, 10].
In the early 1980s, bathhouses were identified as a nexus of HIV transmission. As
a result, bathhouses were the topic of heated debate among public health officials,
government leaders and the gay community [111, 39, 13, 99, 8]. Many states developed
policies to regulate bathhouse behavior; the most extreme of these was advocating
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bathhouse closure [111, 39, 13, 141]. Alternatively, opponents of bathhouse closure
argued that bathhouses could be used as venues to promote HIV and STD prevention
interventions among both high risk and hard to reach populations [137].
By the late 1980s, much of the public debate over bathhouses ended because many
of the bathhouses were shut down [72]. However, many bathhouses are currently
operating around the U.S. in major U.S. cities [72, 142].
Recent research indicates that men who attend bathhouses have been shown to
engage in more sexually risky behavior than those who do not [143]. A case-control
study in New York City showed that MSM with syphilis were more likely to have
visited bathhouses than controls [90]; surveillance data have indicated high rates of
bathhouse patronage among MSM with repeat syphilis infections [32]. A second case
control study from Los Angeles demonstrated that MSM who attend bathhouses and
sex clubs have an increased risk of contracting syphilis as compared to those MSM who
do not patronize bathhouses and sex clubs [73]. Other US and international studies
have shown that bathhouse patronage was associated with hepatitis A, syphilis, and
lymphogranuloma venereum [49].
Some jurisdictions have existing regulations that would provide a basis for the clo-
sure of bathhouses, and doing so has been suggested as a public health intervention to
limit STD and HIV transmission [13, 46]. Historically, most of the policies aimed at
regulating bathhouse behavior have been based on little, if any, data [141]. Alterna-
tively, because they provide access to a population engaging in sexual risk behavior,
they have been and could be used as venues to promote HIV and STD prevention
interventions [137]. Although numerous bathhouse interventions to reduce high risk
sexual behavior have been suggested, developed and implemented, most of these have
not been evaluated for effectiveness [137, 9]. One exception is a study by Woods et al
[141], which assesses how changes in bathhouse architecture, mandated by city-wide
policies, affect the sexual behavior of MSM.
5
Thompson [126] considered the role that a small, yet very high-risk, subset of a
population has on HIV transmission by comparing it to a population with uniform
risk. Since there was very little data regarding HIV available at that time, the model
was constructed so that it would rely on very few parameters. The availability of
behavioral data that enables risk behavior to be differentiated among MSM enabled
us to develop an HIV transmission model that explicitly considers behaviors in various
subpopulations.
We sought to estimate the potential impact of bathhouse closure on HIV transmis-
sion in comparison to an alternative of a reduction in risk behavior by those attending
bathhouses. To accomplish this, we constructed a transmission model based on the
Bernoulli process model of HIV infection originally developed by Steven Pinkerton
and Paul Abramson to determine how the closure of bathhouses would affect HIV
transmission [95]. We extend the model to include subpopulations with different be-
haviors and the presence of syphilis, populate the model with data from a survey of
MSM, and estimate the implications of various bathhouse policies on HIV transmis-
sion.
2.2 Methods
2.2.1 The Mathematical Model
In the Bernoulli process model each sex act is treated as an independent Bernoulli
trial. That is, the probability of infection from one act is a constant and is independent
of all other acts. In our model, we defined the probability of HIV transmission by sex
act and not by partnership due to the detail of the data that we used.1
Let πT be the HIV prevalence of the total population, and αu (αp) be the proba-
bility an individual acquires HIV from one unprotected (protected) sex act with an
1Note that we also modeled the probability of HIV transmission by partnership, and the con-
clusion of whether closing a bathhouse would increase or decrease HIV prevalence does not change.
Readers interested in the details of this analysis can contact the authors.
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HIV infected partner. Note that αp can be represented as βαu where (1−β)∗100% is
the percent effectiveness of condoms. Pinkerton and Abramson [95] established that
the probability (P1) of an individual acquiring HIV after m acts where x% of them
are protected with a single (“main”) partner of unknown HIV status is:
P1 = πT (1 − (1 − αu)(1−x)m(1 − αp)xm). (1)
Similarly, they established that for a person who has n total acts of which y% are
protected each with different (or “non-main”) partners of unknown HIV status, the
probability (P2) of becoming infected is:
P2 = 1 − (1 − πT αu)(1−y)n(1 − πT αp)yn. (2)
We can combine Equations 1 and 2 to find the probability an individual does not
acquire HIV after m contacts with one (main) partner (x percent of which are pro-
tected) and n additional contacts each with different (non-main) partners (y percent
of which are protected).
In this paper, we have extended the Bernoulli transmission framework to account
for different subpopulations, each with different behavioral characteristics and HIV
prevalences. This development will provide the machinery to analyze the effect that
bathhouses have on HIV transmission.
In order to compare different bathhouse policies, we will need to distinguish be-
tween sexual behaviors of those who visit bathhouses and those who do not, as in-
dicated by the data. Indeed, it is useful to consider several different categories of
behavior. To this end, we define “types” of individuals based on a variety of criteria,
and effectively divide the population into subpopulations where all individuals in a
subpopulation have the same type. The data indicate that there may be significant
differences across groups including whether an individual visits bathhouses, has a
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“main” partner, or is HIV+.
Consequently, we first divide the population into individuals who visit bathhouses
and those that do not. Call these subpopulations BH and NB, respectively. Let
πBH (πNB) be the HIV prevalence of BH (NB). For each of BH and NB, we define
two subpopulations based on the presence or absence of a main partner. For those
men who currently have a main partner, their contacts are split between a main
partner and others from the population of MSM at large. Those who do not have
a main partner draw all of their contacts from the population at large. Finally, we
further divide each of these 4 subpopulations by HIV+ and HIV-, for a total of 8
subpopulations (four of which are BH and four of which are NB).
For a given individual in subpopulation i we define:
• mi as the number of sex acts with a main partner
• xi as the percentage of main partner sex acts that are protected
• ni as the number of sex acts with non-main partners
• yi as the percentage of non-main partner sex acts that are protected
Because the effect bathhouses have on the spread of HIV is the main topic of
this study, we are also concerned with the proportion of the sex acts that are with
members of BH. We denote this proportion as z. We define zBH as the proportion of
non-main contacts of members of BH that are with other members of BH. Similarly,
we define zNB as the proportion of non-main contacts of members of NB that are
with members of BH. We can extend the Bernoulli model to express the probability
of a member of BH not acquiring HIV with a partner of unknown HIV status in a
time window of a year by:
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Pxm,ynzBH = [1 − πT [1 − (1 − αp)xm(1 − αu)(1−x)m]]
︸ ︷︷ ︸
A






× (1 − πNBαp)y(1−zBH )n
︸ ︷︷ ︸
D




where we removed the indices on m, x, n, and y for simplicity. Each labeled term
in Equation 3 above represents the probability of not acquiring HIV given a set of
partners and acts. The partners and acts corresponding to each term are described
in words below:
• A: m sex acts with main partner (x percent protected)
• B: yzBHn protected sex acts with non-main partners who are bathhouse patrons
• C: (1−y)zBHn unprotected sex acts with non-main partners who are bathhouse
patrons
• D: y(1−zBH)n protected sex acts with non-main partners who are not bathhouse
patrons
• E: (1− y)(1− zBH)n unprotected sex acts with non-main partners who are not
bathhouse patrons
Now, let Pxm,ynzBH := 1 − Pxm,ynzBH be the probability that one individual from
BH acquires HIV given the set of behavior parameters m, x, n, y, and zBH . A similar
equation exists for the individuals from NB.
If we assume everyone in a given subpopulation has the same behavior parameters,
then 1 - Equation 3 gives the expected number of new HIV cases for that subpopula-
tion. For clarity, let us index the BH subpopulations by i and the NB subpopulations
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by j. Summing over all subpopulations gives us the expected number of new HIV
cases for the population as a whole as
MBH∑
i=1
(Pximi,yinizBH ) ∗ Ni +
MNB∑
j=1
(Pxjmj ,yjnjzNB) ∗ Nj , (4)
where Nk represents the number of people in subpopulation k, and there are four MBH
bathhouse subpopulations indexed by i and four MNB nonbathhouse subpopulations
indexed by j2.
Given a set of parameters, Equation 4 makes it possible to compare the average
total number of new infections in a year given that a bathhouse is open or closed. It
is clear that the parameters zBH and zNB, indicating the degree of mixing between
BH and NB, will be different depending on whether the bathhouse is open or closed;
we estimated these values from the data. We also examined the impact of other
differences in behavioral parameters to indicate changes brought on by policies, system
changes, or interventions.
For analysis on the subpopulations to be accurate, certain identities must hold.
For example, the number of sex acts that the members of BH have with NB can be
calculated from the data as the number of total acts by a BH individual times the
percentage of those acts outside the bathhouse times the proportion of those acts with
the NB population. The number of sex acts that the members of NB have with BH
can correspondingly be calculated from data as the number of total acts by an NB
individual time the proportion of those acts with the BH population. Clearly these
two number of sex acts should be the same. Similarly, the number of protected and
unprotected acts each must also match. However, survey data on sexual behavior will
for a variety of reasons contain some inaccuracies, and as result, the identities will
not precisely hold. Even if every member of the population is sampled in the survey,
2For bathhouse and nonbathhouse, the subpopulations are {main/HIV+, main/HIV-, no
main/HIV+, no main/HIV-}.
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it is possible that someone reports having a sex act in the survey, but his partner does
not report it. It is also possible that they recalled their condom usage during the act
differently. Additionally, we are using averages within each of the subpopulations,
i.e., we do not explicitly model each individual’s behavior, and not all individuals
within a community were included in the survey. In our results we therefore used an
error tolerance of 33%. That is, we only considered data points of our parameters if
each of these described identities had an error of less than 33%.
2.2.2 Including Syphilis
The presence of primary or secondary syphilis (P&S) has been shown to dramatically
increase the probability of HIV acquisition and transmission. Estimates of this in-
crease range from 3-15 times the probability without syphilis, though most studies
have focused on heterosexual transmission and many have combined all genital ulcera-
tive diseases together (including chancroid and genital herpes simplex virus infection)
[105, 125, 132]. Because of the increase in syphilis rates among MSM in major US
cities [92], the model may more accurately reflect transmission under varying scenarios
if syphilis can be incorporated.
Because we included the effect of syphilis into the model by using the same process
as the previously-described model, and the equations become much more cumbersome,
we will simply provide a qualitative explanation and provide mathematical details in
the Appendix.
In the most specific consideration, syphilis can change the rate of infectivity of
an individual in different ways depending on whether the individual without HIV
has syphilis, whether his partner has syphilis, or whether both have the disease.
To calculate the probability of infection for a susceptible individual, we use a similar
method as in Equation 3 but extend the equation to incorporate changes in infectivity
rates depending on whether one of the partners, both, or none have syphilis.
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To extend the model, we take into the account the susceptible individual’s syphilis
status and the proportion of their contacts that are with syphilis positive individu-
als. The former implies that the total number of subpopulations under consideration
will double (positive or negative for syphilis). The latter is determined simply by
the syphilis prevalence of the corresponding subpopulation. When neither individual
with sexual contact has syphilis, the same infectivity rates are used as before. When
the individual in question has syphilis but his partner does not, the appropriate trans-
mission probability (αu or αp) is multiplied by some constant, a. When the individual
in question does not have syphilis but his partner does, the appropriate transmission
probability is multiplied by a different constant, b. When both individuals in question
have syphilis, the appropriate transmission probability is multiplied by yet another
constant, c. See Equations 12 and 13 in the Appendix for the full model. This general
model can also be simplified for the case when the infectivity rates are not different
for all of these combinations by making the constants a = b = c.
2.2.3 Analytics
We show that the HIV attack rate is concave as a function of zBH . This result is useful
because the data in the subsequent section indicate that zBH is greater than where
the maximum of the concave function occurs regardless of whether bathhouses are
open or closed (given that the number of contacts remains the same in both scenarios).
Consequently, a decrease in zBH (resulting from bathhouse closure) causes an increase
in the HIV attack rate. The intuition is that the increase in zBH benefits the low
risk group more than it harms the high risk group causing an overall decrease in the
number of HIV cases. Data cited in the literature (cite Woods letter) supports the
hypothesis that the number of contacts will remain near constant in both scenarios,
and hence we can use the concavity result to conclude that the HIV attack rate will
increase with bathhouse closure.
12
Equation 3 defined the probability of an individual of the bathhouse population
characterized by the parameters x, m, y, n and zBH not acquiring HIV as
Pxm,ynzBH = [1 − πT [1 − (1 − αp)xm(1 − αu)(1−x)m]]
︸ ︷︷ ︸
A






× (1 − πNBαp)y(1−zBH )n
︸ ︷︷ ︸
D




but it can easily be re-written as
Pxm,ynzBH = [1 − π[1 − (1 − αp)xm(1 − αu)(1−x)m]]
× [( (1 − πBαp)
(1 − πBαu)
∗ (1 − πNαu)
(1 − πNαp)















c = [1 − π[1 − (1 − αp)xm(1 − αu)(1−x)m]] (9)
then we can re-write this equation as
Pxm,ynzBH = (a
y ∗ b)zBHn ∗ c (10)
which is a convex function of zBH since (a
y ∗ b) is always positive.
We can arrive at a similar expression for the NB population. Since zNB is a linear
function of zBH , Pxm,ynzNB for the nonbathhouse patrons is also a convex function
of zBH . Finally, since the negative of a convex function is concave, and the sum of
concave functions is concave, equation 4 is a concave function of zBH .
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2.2.4 Data
The primary data source for behavioral data was the Urban Men’s Health Study
(UMHS), which was conducted in 1997 and has been described elsewhere [15]. Briefly,
the survey was conducted via telephone in four urban centers (San Francisco, Los
Angeles, New York City, and Chicago) and focused on geographical areas that were
believed to contain the majority of MSM in each city. Survey participants were MSM
and were asked about the number of sex partners in the last year overall, and about
the number of sex partners with whom they had engaged in receptive or insertive
anal intercourse, as well as other behaviors. They were also asked about venues in
which they met sex partners and about condom usage. For their four most recent sex
partners, they were asked about behavior, condom usage, and the venue where they
met the specific partner. All behavioral data were taken from this survey, as were
data for the HIV prevalence in the BH and NB MSM populations.
Data from UMHS were used to define the subpopulations (BH and NB, HIV-
infected and non-infected) and partnerships (main and non-main) described in the
model section. Where variable values for the subpopulations were not different at
p < 0.05, we used the overall mean for the variable in question. Because the data for
the last four partners were specific by partner and less likely to be subject to recall
error, we used the last four partners to determine the rates of condom usage, number
of sex acts, and for BH MSM, the proportion of sex acts with non-main partners that
occurred with a partner met at a bathhouse venue. The means for each variable were
calculated using all non-missing values for the respective field in the data, rather than
discarding observations that had missing values for some fields. Only anal sex acts
were considered as risky sex acts for the model. See Table 1 for a summary of the
survey data and significance across subpopulations.
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Table 1: Summary of data from the 1997 Urban Men’s Health Study. Any differences
in values shown are significant at the 0.05 level.
Total Population (11,646 MSM)
Bathhouse patrons Non-bathhouse patrons
29.4% 70.6%
w/ main partner w/out main partner w/ main partner w/ out main partner
41% 59% 49% 51%
HIV+ HIV- HIV+ HIV- HIV+ HIV- HIV+ HIV-
25.4% 74.6% 25.4% 74.6% 16.5% 83.5% 16.5% 83.5%
Number of non-main sex acts in last 12 months
128.98 58.59 141.22 70.83 16.64 11.18 28.87 33.99
Percentage condom usage with non-main partners
76.0% 83.0%
The distinction between those that have a main partner and those who do not
was determined by the survey respondent citing he had a special commitment to or
was in love with a particular person. The number of acts that are with main partners
is 34.65, and the estimated condom usage with main partners is 58%. Neither of
these are significantly different across subpopulations. Based on data from the last
four partners, approximately 22% of the bathhouse patrons’ non-main sex acts occur
in the bathhouse. This implies that 78% of their non-main sex acts occur outside
of the bathhouse which are distributed among bathhouse patrons and non-bathhouse
patrons. The way in which we distribute the acts outside of the bathhouse is as follows:
If there are 2 bathhouse patrons who have 10 acts each outside of the bathhouse and
10 non-bathhouse patrons who have 5 acts each outside of the bathhouse then there
are 2*10 + 10*5 = 70 total acts to be distributed outside of the bathhouse. 2*10/70
* 100% is the percentage of the acts that any given member of either population has
with bathhouse patrons while outside of the bathhouse when the bathhouse is open.
The true value using data from Table 1 is 54.4%. Multiplying the true value with the
percentage of BH acts that take place outside the bathhouse (78%), we obtain the
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percentage of BH acts outside the bathhouse that take place with other BH patrons.
This also gives us the number of BH acts with BH patrons outside the bathhouse,
and by adding the number of acts within the bathhouse (22% of the BH total acts),
we obtain the number of acts of BH with BH. By converting this to percentages,
we estimate that 64.3% of the bathhouse patrons’ non-main sex acts are with other
bathhouse patrons. That is, the total acts between BH patrons includes the non-
main acts that are in the bathhouse plus the remainder of their sex acts outside the
bathhouse but divided among the overall population, some of which are with other
bathhouse patrons and some of which are not. Given a percentage of the bathhouse
patrons non-main sex acts that are with other bathhouse patrons, we can derive the
percentage of sex acts that non-bathhouse patrons have with bathhouse patrons in
order to account for the total sex acts of the population.
When bathhouses are closed, we assume that all non-main sex acts are drawn
uniformly from the total number of sex acts in the population, which is based on the
population sizes of BH and NB and the number of sex acts of each group. In this case,
an estimated 60% of the (would be) bathhouse patrons’ non-main sex acts are with
other (would be) bathhouse patrons. That is, in the absence of bathhouses, there is
a “natural” mixing of the entire population, whereas the presence of the bathhouse
skews this mixing so that bathhouse patrons have relatively more sex acts with each
other. Therefore zBH is always smaller when bathhouses are closed than open.
Data for the probability of HIV transmission, protective effect of condoms, preva-
lence of P&S syphilis, and syphilis multiplier effect were taken from the literature.
See Table 2 for the variables, their abbreviation in the model, baseline values, ranges,
and sources.
3In our calculations, the same value for increased likelihood of HIV transmission was used re-
gardless of whether either partner or both partners had syphilis. Hence a = b = c = 3.
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Table 2: Epidemiologic variables used for base case and sensitivity analysis along
with corresponding references.
Variable Value Range References
Per-act HIV transmission risk (α) 0.01 0.005-0.03 [37, 131]
Protective effect of condoms (1 − β) 0.9 0.90-0.95 [94]
Syphilis prevalence (P&S) (Πs) 0.005 0.001-0.05 [20]
Syphilis multiplier effect (a, b, c)3 3 3-15 [105, 125, 132]
2.3 Results
Results are reported by computing the annual HIV attack rates. The HIV attack
rate is defined as the number of new HIV cases in a year divided by the number
of susceptible people (i.e., people currently without HIV) in the populations under
consideration. It is useful in demonstrating relative degrees to which the epidemic is
spreading under different scenarios.
Figure 1 shows the HIV attack rate given the number of acts as listed in the data
section with 80% condom usage for the non-bathhouse population, 75% condom usage
for the bathhouse population, an overall syphilis prevalence of 0.5%, and a syphilis
multiplier of 3. The attack rate is shown as a function of zBH , that is, a function
of the percentage of the bathhouse patrons’ non-main sex acts that are with other
bathhouse patrons. In this figure, we make all calculations under the assumption that
the total number of sex acts is the same under both scenarios of bathhouses closed
and open. We will also examine the sensitivity of the results to this assumption in
later analysis.
In all results that we have seen, the attack rate can be closely approximated by a
linear relationship, as depicted in Figure 1. In general, the attack rate can be shown
to be a concave function with respect to zBH . In addition, for the given data, the
attack rate is a strictly decreasing function of zBH . This monotonicity is significant
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Figure 1: HIV attack rate as a function of zBH when the Bathhouse Patron Condom
Usage (BHP CU) is 75%, Non-bathhouse patron condom usage is 80%, overall syphilis
prevalence is 0.5%, and the syphilis multiplier is 3.
closed. This conclusion is a consequence of the attack rate being decreasing and that
zBH will always be larger when the bathhouses are open than when the bathhouses are
closed given that the number of acts remain the same. Consequently, it follows that
under the stated assumptions, the attack rate will increase with bathhouse closure.
In experiments using other values for behavioral parameters, we have found that the
decreasing nature of the function is driven by the relatively larger number of non-
main acts of the bathhouse patron population and the higher HIV prevalence of the
bathhouse patrons. Single points on Figure 1 indicate the points corresponding to
bathhouses being open or closed.
Figure 2 compares the effects of varying rates of condom usage and the number of
acts to the effect of bathhouse closure on the attack rate. The top curve is calculated
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% BH patrons' acts with other BH patrons (zBH)
Figure 2: HIV attack rate for varying levels of Bathhouse Patron Condom Usage
(BHP CU) and Bathhouse Patron Act Reduction due to bathhouse closure (BHP
AR), with other parameters set as in Figure 1.
The two curves below it represent the attack rates when the condom usage of the
bathhouse population increases by 5 percentage points (to 80%) and 10 percentage
points (to 85%), respectively. Each of these three curves are calculated under the
assumption that there is no change in the number of sex acts in the event of bathhouse
closure.
The three individual scatter points, on the other hand, represent the attack rates
calculated with the parameter values for Figure 1 with the bathhouse open but where
the number of sex acts for the bathhouse population does decrease in the event of
bathhouse closure. The analysis is done for several values of the potential percentage
reduction in the bathhouse patrons’ non-main partner sex acts that took place in the
bathhouse. The reduction in acts is referred to as Bathhouse Patron Act Reduction
(BHP AC) in the figure. The remainder of the acts (including non-main partner acts
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outside of the bathhouse and main partner acts) are assumed to be unchanged. An
entire curve is not traced in this case since the bathhouse is assumed closed making it
unnecessary to plot it as a function of zBH ; we only consider the non-skewed “natural”
mixing of the population which occurs when the bathhouse is closed corresponding
to one value of zBH and hence one point on the graph. Note that the “natural”
percentage of bathhouse patrons’ acts with other bathhouse patrons with bathhouses
closed decreases as the number of sex acts is scaled down since they are having fewer
acts.
Under the stated assumptions, this result suggests that increasing BH condom
usage from 75% to 80% has a much larger effect on the attack rate than a bathhouse
closure. Similarly, a change in the number of sex acts also has a much larger effect
on attack rate than that of closure alone, that is, if the reduction in sex acts with the
bathhouse closed were sufficiently large, then closing the bathhouse could be effective
in reducing HIV transmission. This would assume that the bathhouse patrons were
not able to replace their bathhouse sex acts by meeting sex partners in other venues.
Not shown on the graphs, but also noteworthy, is that the effect of bathhouse closure
is roughly equal to a 0.2% change in the condom usage of the bathhouse patrons.
Figure 3 demonstrates the effects that our assumptions regarding syphilis have on
the results. We consider syphilis prevalence values of 0.5%, 5%, and 10% (the bottom
three curves, respectively). Additionally, whereas all previous results assumed that
the presence of syphilis caused the probability of infection per sex act to increase by
a factor of three, Figure 3 considers the case where syphilis causes the probability of
infection to increase by a factor of 15 (top curve). We consider this sensitivity since
there is variation in the literature on the effect of syphilis.
It should be noted that while the graph in Figure 3 will vary with different values
of the syphilis multiplier effect and the underlying syphilis prevalence, the overall
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Figure 3: HIV attack rate for different Syphilis Prevalence (SP) and Syphilis Mul-
tiplier Effect (SME) values, where Bathhouse patron condom usage is 75% and Non-
bathhouse patron condom usage is 80%.
be a decreasing function of zBH , and as a result bathhouse closures are expected to
create an increase in the attack rate unless the reduction in acts is large enough.
Table 3 shows sensitivity on attack rate for different parameter values. In this
table, the base case corresponds to the base case parameter values as listed in Table
2. All other attack rates correspond to the base case parameter values except where
explicitly stated (e.g. alpha = 0.005 corresponds to the base case parameter values
except that alpha is changed from 0.010 to 0.005). The best case scenario corresponds
to the parameter values that will produce the lowest attack rate, namely α = .005, (1-
β) = 0.95, πS = .001, and syphilis multiplier = 3. The worst case scenario corresponds
to the values that will produce the highest attack rate, namely α = .030, (1-β) =
0.900, πS = .050, and syphilis multiplier = 15. Notice that although the magnitude
of the attack rate values change, it remains higher for the case of open versus closed
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Table 3: Annual attack rate for different parameter values. The base case corre-
sponds to the values reported in Table 2.
BH BH 50% BHP 80% BHP 80% BHP
closed open AR after CU BH CU BH
BH closure closed open
Best case scenario 0.0165 0.0165 0.0158 0.0156 0.0156
Alpha = .005 0.0187 0.0186 0.0178 0.0178 0.0177
95% condom effectiveness 0.0328 0.0328 0.0314 0.0310 0.0309
Base case 0.0365 0.0364 0.0348 0.0347 0.0346
Alpha = 0.030 0.0997 0.0995 0.0960 0.0958 0.0954
Worst case scenario 0.1685 0.1678 0.1614 0.1611 0.1603
bathhouses.
We have assumed that sexual activity remains the same during bathhouse closure.
It is possible that sexual activity would decrease after bathhouse closure, though we
have no data on this issue. In Figure 4 we show the resulting HIV attack rate
from bathhouse closure as a function of percentage decrease in sexual activity. The
base case for an open bathhouse from Figure 1 is shown as a horizontal dashed
line for comparison. It is assumed that the base case of BH condom usage is 75%,
non-bathhouse condom usage is 80%, overall syphilis prevalence is 0.5%, and the
syphilis multiplier is 3. From this figure we see that if bathhouse closure leads to
a reduction of bathhouse patrons’ sexual activity within the bathhouse of at least
2%, HIV transmission would be reduced as compared to keeping the bathhouse open.
Note that part of the reason for the decreased HIV attack rate with decreased sexual
activity is that the relative percentage of sexual acts with condom usage increases.
2.4 Discussion
The results of the model suggest that, given the characteristics of the MSM population
of the four survey cities (and the assumption that these characteristics do not change)
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Figure 4: HIV attack rate for bathhouse closure as a function of the percentage
decrease in BH sexual activity within the bathhouse due to bathhouse closure. BH
condom usage is 75%, non-bathhouse condom usage is 80%, overall syphilis prevalence
is 0.5%, and the syphilis multiplier is 3. The horizontal dashed line is for the base
case of keeping the bathhouse open.
magnitude of the effect of the closure would be small compared to the effect of a
change in condom usage or the number of sex acts. Therefore, these results need to
be coupled with other studies. That is, if one can show that condom usage will not
change, but the number of sex acts will decrease dramatically as a result of closure,
then Figure 2 suggests that bathhouse closure would lead to a decrease in the attack
rate. Conversely, if by leaving the bathhouses open one can show that condom usage
will increase (by, for example, condom usage enforcement or promotion/education at
the bathhouse venue) then the policy of keeping bathhouses open may result in a
lower HIV attack rate. Indeed, leaving bathhouses open facilitates such intervention
programs since it makes access to the MSM group with the highest prevalence and
highest number of sex acts much more reachable. However, one study has found little
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effect on risk behavior of bathhouse policies focused on regulating the amount of
public versus private space in the facilities. The authors suggested that such policies
may have moved risk behavior of BH patrons to different venues, rather than causing
it to decline [139]. The impact of these and other potential interventions remains
speculative, because there has been little evaluation [10, 137].
The results must be interpreted under consideration of the model’s limitations.
First and foremost, as a single stage model it only serves as a short term prediction as
it ignores the effects of secondary infections. It does not differentiate between acute
and chronic HIV infection. Evidence in the literature suggests that HIV infectivity
differs over time. Wawer et al. [132] state that HIV infectivity is much higher during
the acute stage (3 month period following initial infection) than during the chronic
stage which is compounded by the fact that during the first three months the virus
has likely not been detected. On the other hand, Rapatski et al. [100] find that most
of the transmission occurs in the later stage of the disease. Either way, it could be
important to have a model that can capture temporal differences in HIV infectivity.
If the aforementioned factors were included, it is possible that the graph in Figure 1
could become steeper. This steepness, or lack thereof, however, is what determines
how the effect of bathhouse closure compares with a change in condom usage and
number of sex acts. A change in steepness could possibly result in a different conclu-
sion regarding the role of bathhouses in HIV transmission when changes in behaviors
are considered.
An additional limitation of the model is that some of the data estimators for the
parameters included in the model rely on the survey respondent’s last four partners.
The assumption that a respondent’s condom usage behavior over the course of an en-
tire year is accurately reflected by their condom usage with their last four partners, for
example, may not always be valid. Moreover, the survey only includes city residents
of four US cities and does not reach the surrounding areas, which may contain MSM
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who visit city bathhouses. The UMHS survey, however, is the most comprehensive
to date.
Another factor that we did not consider was club (recreational) drug use. The use
of club drugs such as crystal methamphetamine has been shown to increase sexual
risk-taking behavior and is associated with increased HIV/STD transmission [33, 34,
70]. Research has documented the prevalence of club drugs at specific gay events such
as circuit parties. It is possible that many bathhouse patrons use substances prior
to arriving at the venue. However, it may also be possible that bathhouse patrons
acquire substances from other bathhouse patrons. Environment may influence club
drug usage, and by extension risk behavior, suggesting that if bathhouses were closed,
club drug usage preceding sex could diminish. We should mention that although we
did not have accurate estimates of the prevalence of drug use in bathhouses, the
model could be easily extended to determine the impact of drug use on transmission
by using the same approach we used for including syphilis, and it is possible that
drug use is already incorporated in the survey responses, since the condom usage was
lower among bathhouse patrons.
The Centers for Disease Control and Prevention estimate that 25% of the US pop-
ulation who are HIV positive does not know it [26] Unfortunately, the data available
from the UMHS survey did not allow us to model knowledge of infection. If the data
were available, we could create new classes of those that know they are infected and
those that do not, in the same way that syphilis was modeled.
Lastly, an implicit underlying assumption in our model is that the disproportionate
mixing of the bathhouse and non-bathhouse populations will be eliminated as a result
of bathhouse closure. That is, those who were bathhouse patrons prior to closing
would no longer disproportionately have more sex with each other than the rest of
the population after closure. This assumption seems quite intuitive in the short
term. However, the bathhouse patrons would still remain high activity members of
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the population in terms of partner numbers. As time passes, it is unpredictable the
degree to which the high activity members would organize private venues similar to
the bathhouse through, for instance, coordination via the Internet. Recent literature
already suggests that the Internet is serving as a “cyber-bathhouse” in the sense that
many high activity or high risk MSM can easily arrange private environments similar
to bathhouses, with even less regulation than in bathhouses [12].
In future work, we plan to extend this model to a multi-stage setting. One of
the benefits of this extension is that, it will eliminate some of the aforementioned
limitations. A multi-stage model will also be useful in determining the importance
of modeling subpopulations when considering HIV transmissions, since the impact of
transmissions is compounded over time.
2.5 Appendix
In order to incorporate the effects of syphilis, we divided each subpopulation above
further by whether the individuals are positive or negative for syphilis. The probabili-
ties of HIV infection will be different for each of the subpopulations. When populating
our earlier HIV transmission model, we had data that indicated the number of sex
acts by subpopulation. However, when we expand the model to include syphilis sta-
tus, our data does not specify which partners have syphilis, so we take an expectation
over the syphilis prevalence in the corresponding population to determine the number
of acts across each of the subpopulations.
For an individual from BH who is positive for syphilis, his probability of not
acquiring HIV with the behavior parameters x, m, y, n, and zBH is given by:
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PPxm,ynzBH = [1 − πT [πS[1 − (1 − cαp)xm(1 − cαu)(1−x)m] (11)
+(1 − πS)[1 − (1 − aαp)xm(1 − aαu)(1−x)m]]]
︸ ︷︷ ︸
A+B






× (1 − πNBcαp)y(1−zBH)πSn
︸ ︷︷ ︸
E
(1 − πNBcαu)(1−y)(1−zBH )πSn
︸ ︷︷ ︸
F
× (1 − πBHaαp)yzBH(1−πS)n
︸ ︷︷ ︸
G
(1 − πBHaαu)(1−y)zBH (1−πS)n
︸ ︷︷ ︸
H
× (1 − πNBaαp)y(1−zBH )(1−πS)n
︸ ︷︷ ︸
H




where the indices are suppressed again for clarity. For an individual from BH who is
syphilis negative, his probability of not acquiring HIV with the behavior parameters
x, m, y, n, and zBH is given by:
PNxm,ynzBH = [1 − πT [πS[1 − (1 − bαp)xm(1 − bαu)(1−x)m] (12)
+(1 − πS)[1 − (1 − αp)xm(1 − αu)(1−x)m]]]
︸ ︷︷ ︸
A+B
× (1 − πBHbαp)yzBHπSn
︸ ︷︷ ︸
C
(1 − πBHbαu)(1−y)zBH πSn
︸ ︷︷ ︸
D
× (1 − πNBbαp)y(1−zBH)πSn
︸ ︷︷ ︸
E
(1 − πNBbαu)(1−y)(1−zBH )πSn
︸ ︷︷ ︸
F
× (1 − πBHαp)yzBH(1−πS)n
︸ ︷︷ ︸
G
(1 − πBHαu)(1−y)zBH (1−πS)n
︸ ︷︷ ︸
H
× (1 − πNBαp)y(1−zBH )(1−πS)n
︸ ︷︷ ︸
I




As before, each labeled term in the equations above represents the probability of
not acquiring HIV given a set of partners and acts. The partners and acts corre-
sponding to each term are described in words below:
• A + B: m sex acts with main partner who is syphilis positive x percent of
which are protected (weighted with probability πS), and m sex acts with main
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partner who is syphilis negative x percent of which are protected (weighted with
probability (1 − πS))
• C: yzBHπSn protected sex acts with non-main partners who are bathhouse pa-
trons and syphilis positive
• D: (1 − y)zBHπSn unprotected sex acts with non-main partners who are bath-
house patrons and syphilis positive
• E: y(1− zBH)πSn protected sex acts with non-main partners who are not bath-
house patrons and are syphilis positive
• F: (1 − y)(1 − zBH)πSn unprotected sex acts with non-main partners who are
not bathhouse patrons and are syphilis positive
• G: yzBH(1−πS)n protected sex acts with non-main partners who are bathhouse
patrons and syphilis negative
• H: (1 − y)zBH(1 − πS)n unprotected sex acts with non-main partners who are
bathhouse patrons and syphilis negative
• I: y(1 − zBH)(1 − πS)n protected sex acts with non-main partners who are not
bathhouse patrons and are syphilis negative
• J: (1− y)(1− zBH)(1− πS)n unprotected sex acts with non-main partners who
are not bathhouse patrons and are syphilis negative
We can combine Equations 12 and 13 to represent the total number of new HIV
cases for all BH subpopulations by:
MBH∑
i=1
[1 − (1 − πS)PNximi,yinizBH − (πS)PPximi,yinizBH )] ∗ Ni, (13)
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where there are 8 MBH BH subpopulations indexed by i, and Ni members in subpop-
ulation i. With an identical development we can include the NB subpopulations in
Equation 13 and it will have the same form as Equation 3, the only difference being
each population is split into two groups by syphilis status, and each corresponding
probability of infection is more complicated. The total number of new HIV cases for
the entire population is then represented by:
MBH∑
i=1




[1 − (1 − πS)PNxjmj ,yjnjzNB − (πS)PPxjmj ,yjnjzNB)] ∗ Nj, (14)




TIMING OF TESTING AND TREATMENT FOR
ASYMPTOMATIC DISEASES
3.1 Introduction∗
Recommended testing protocols to determine the presence of a disease have two major
components. First they must specify the population to be tested (i.e., universal testing
or targeting). Second, they must specify the timing and frequency of testing, that
is, one-time testing, routine testing, or intermittent testing. If it is the latter, they
must also specify the time interval between tests and whether the interval should
be constant or varying. Although current guidance typically (though not always)
specifies the population to be tested, it is often silent as to the frequency and the
timing of testing. Timing can be important because it can impact whether testing is
cost-effective in a population.
Several criteria are considered when determining the optimal testing protocol.
These include the prevalence of the disease, accuracy of the test, whether awareness
of disease status reduces costs, the associated costs of the disease and test, and how
the disease progresses. As disease prevalence decreases, more persons must be tested
to identify one case and thus targeting tests to at-risk persons may be more efficient.
However, if the cost of the condition is high relative to the cost of the test, universal
testing may be more cost-effective. Awareness of disease status will influence costs
if an effective intervention to treat the disease is available or if changes in personal
behavior can reduce future morbidity, mortality, or probability of transmission to
others. For example, a person who learns he has Hepatitis C (HCV) may reduce
∗This chapter is a collaborative effort with H. Eser Kirkizlar.
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his alcohol intake, which would reduce the probability of future liver damage. In
addition, if he were an injection drug user (IDU), he could participate in a needle
exchange program, which would reduce the likelihood of transmission to others.
Our motivation is to study testing and treatment protocols from a societal per-
spective. We specifically focus on the time to test an individual one or more times for
a disease. We use a Markov Decision Processes (MDP) approach to model the disease
progression and testing decision, where the reward function (or utility) is based on
testing and treatment costs, quality adjusted life years (QALY) defined in different
stages of disease, and the cost of infecting other individuals. We also allow the aware-
ness of the presence of the disease to affect behavior, which can change the transition
probabilities and secondary infection costs after testing. We analyze the model for
structural results and find sufficient conditions to establish when testing (and treat-
ing) the disease is cost-effective, and provide insights for healthcare practice. We
demonstrate the results for HCV using medical data, and compare our findings to
current HCV screening recommendations. We also solve for the threshold incidence
for a population group beyond which testing is cost-effective.
The Chapter is organized as follows. A brief literature review is given in the
next section. In Section 3.3, we describe the Markov model for a general disease
setting, and present structural results for the MDP. Then in Section 3.4, we perform
a numerical study for HCV using data obtained from patient studies and health
databases. Finally, we discuss the implications of our results and several directions
for future research in the last section.
3.2 Literature
We briefly summarize past work in HCV screening and treating as it relates to our
work; this is in no way a complete review of the literature. Several researchers have
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modeled treatment of HCV and have in general found it to be cost-effective for popu-
lations who are known to have the disease [62, 107]. The literature on testing for HCV
is much less clear. For example, Castelnuovo [14] find based on a decision analytic
model that testing is cost-effective in injection drug users; Gordon [54] also reports
that testing can be cost-effective for high-risk groups. However Plunkett [96] finds
screening of asymptomatic pregnant women for HCV infection is not cost-effective.
In addition, Singer [114] found that routine HCV testing was not cost-effective in
asymptomatic, average-risk adults. Pereira [91] used a Markov simulation model to
show that although testing blood donors for HCV was cost-saving for the health care
system, screening of post-transfusion patients was not; this is likely because most
HCV-infections due to transfusions have already been identified. Note that the liter-
ature on cost-effectiveness for screening of HCV does not explicitly consider the age
as part of the decision process, which is a factor we will consider in this Chapter.
Testing recommendations from public health agencies can also differ. For example,
the US Public Health Service (USPHS) and Infectious Diseases Society of America
(IDSA) recommend testing of all HIV positive persons for HCV [16]. The US Preven-
tive Services Task Force (USPSTF) recommends against routine testing for HCV in
the general population and makes no recommendation for populations with high risk
for infection [128]. The Centers for Disease Control and Prevention (CDC), on the
other hand, does recommend routine testing for population groups with a high risk
for acquiring HCV such as drug users or commercial sex workers [19]. However, none
of these agencies make recommendations about the frequency or timing of testing.
Explicit consideration of timing could change the recommendations.
Our work in HCV testing and treating differs from previous work in that we
explicitly model the timing decision of the testing and explicitly consider behavior
change as a result of knowledge of infection from testing. The former is possible
because of the Markov decision process model that we develop and study. In addition,
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we compare different strategies for the number of tests.
There have been numerous papers in the medical literature using Monte Carlo
simulation of Markov models to study disease progression or screening for other dis-
eases (e.g., [53, 103, 116]) In most of these papers, the progression of the disease is
modeled as Markovian, and cost-effectiveness of a specified testing policy is calculated
using simulation across a population group with particular risk characteristics. The
simulation medical papers often address whether to screen the risk group in question,
although fewer address when the screening should be performed, which can affect
cost-effectiveness. The definition of the risk group may include an age range (which
is an implicit way of capturing timing), but this may not be sufficient to capture
the progression of the disease and behavior over time. Example papers that examine
cost-effectiveness of repeated screenings where a limited number of testing policies
are specified a priori include [11, 74, 130, 84]. Diehl [38] studies a large number of
screening policies for disease where over 1000 testing policies for breast cancer are
evaluated.
Analytical approaches may complement the simulations and help to provide addi-
tional insight on the characteristics of the testing policies, and there are also relevant
papers that have used analytics for screening decisions. Some of these papers also re-
late to scheduling examinations or replacements for machines in a production system,
although papers in this area may have different assumptions than those that focus
on medical decisions. Early operations research approaches to this problem include
Smallwood [115] and Kirchklein [63], both of which have perfect testing information
and stationary parameters; the first is an early example of POMDPs with medical
implications. Lee [65] finds that the optimal screening is equally spaced if tests have
perfect reliability, although other papers have found that spacing may not be equal if
parameters vary over time. Examples of papers that primarily focus on inspection of
production systems include [135, 75, 76, 82, 144]. One key assumption in these papers
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is that the testing procedure does not impact the performance of the machine unless
a corrective action is taken. An important aspect of our problem is the behavioral
change brought on by awareness of the disease gained through testing, i.e., we can
have “partial” treatment at no cost.
One of the more relevant papers from the inspection literature is Ozekici [83],
which uses a simplified version of a POMDP that the authors then transform into an
MDP with complete information. The authors include false positives and negatives
for the test but allow no death from causes other than disease and no recurrence of
disease (thus no testing after disease has been treated). Houshyar [58] allows death
from causes other than disease and formulates a screening problem where the disease
progression can be modeled with a discrete-time Markov chain. He gives guidelines
for calculating the costs as well as the transition probabilities and applies the model
to a disease but does not study structural results of the problem.
Zelen [147] focuses on medical screening timing along with follow-on papers [67]
and [66]. These papers focus on a weighted utility function that is linear in the
probability of finding a case and being incident between tests; they focus on testing
when probabilities are stationary over time, or not age-dependent, while in our case
risk behaviors or disease progression may depend on age. Other papers that study
screening problems but have stationary parameters include Monahan [77] and Par-
mogiani [88]. An interesting approach is taken in Kaplan [61], where the authors use
an analytical model similar to inventory modeling to show that the interval between
screenings depends on the prevalence in the population, and apply the model to HIV.
Parmigiani [86] uses a non-Markovian stochastic model to solve for test timing
and takes into account the effect of age on disease progression. Parmigiani [87] finds
an exact solution with fallible tests and two disease states. As in our case, the latter
paper only gains information about disease presence by use of a test, although in the
second paper tests take a random amount of time and do not alter the state of the
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system. We also use a higher number of disease states and allow recurrence of the
disease and death from causes other than disease. Special cases with two (or even
three) states have also been considered in other papers including some above but also
others, e.g., Eddy [43] and Grosfeldnir [55], although under different assumptions than
the ones we use. Specifically, Grosfeldnir [55] consider a production system and the
only states are “good” or “bad”, and the actions available are to replace to machine
or not. Others have considered the special case of one or two tests over the time
horizon, such as in [86, 89, 77]. In our case we are able find explicit conditions for a
dynamic testing and/or treating strategy to be beneficial. That is, we do not restrict
the number of tests beforehand.
The subject of using MDPs and POMDPs to model medical screening problems is
discussed in Hauskrecht [56], where POMDPs may be used to capture informational
aspects. As the authors state, even the definition of the POMDP may be difficult
for a disease, and the number of transitions and probabilities to define can become
“practically impossible”. They use a hybrid POMDP with an MDP and use approx-
imations to solve it with data from ischemic heart disease, but they point out that
other structural refinements are possible to make the models reasonable to define and
solve.
To summarize, our research contributes to the literature on medical screening
by developing and analyzing a special case of a POMDP model for the timing of a
screening test for a disease that may have secondary infections. Key aspects include
a transition probability matrix that changes with the actions and states to model
behavioral changes. We find some analytical results on the timing of disease screening
and interpret these for policy implications.
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3.3 Model and Structural Results
3.3.1 The Mathematical Model
We formulate the progression of the disease as well as the testing and treatment
decisions as a finite-horizon, discrete time discounted MDP model. We allow the
health states to be partially observable, with the test providing the only update in
information regarding the current health state. In the description of the model we will
focus on the maximization of utility. The utility is based on QALYs for the different
states of health of a person as well as the cost of testing, treating, and corresponding
complications. Note that costs may be converted to QALYs using a cost-effectiveness
threshold, e.g., $50,000 per QALY [29]. We assume that false positive tests can result
but a second test is available with higher accuracy, which reflects common practice.
In our base model we will analyze the model with a test that has high sensitivity but
we will describe how the model and results extend to tests with false negatives.
Let S ⊂ ({(h, i)|h ∈ {0, . . . , H}, i ∈ {0, 1}} be the state space of our stochastic
process. We use h ∈ {0, . . . , H} to denote the health state of the individual (note
that in the remainder of the Chapter we will use “health state” to refer to the first
component of the state space). 0 is the state individual is healthy and H is the state
individual is dead, with the other states representing disease states that may have
different utilities, transition probabilities, or other characteristics. An individual’s
belief about whether or not he has the health condition is denoted by i; 0 is used for
the case that he thinks he is healthy and 1 for the case that he knows that he has
the disease. The probability of having the disease (e.g., determined by the prevalence
in the population to which the individual belongs) is only updated by the use of a
screening test. This simpler representation of a partially-observable MDP is used to
capture the issue of awareness of disease, and it reflects testing as the primary way
to determine presence of a disease.
A = {NT, T1, T2, T1T2} denotes the action set and As denotes the feasible actions
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for every s ∈ S, where As ⊆ A. The action NT denotes “do not test” option, T1
denotes “test but do not treat if the individual is sick” option, T2 denotes “treat the
individual if he is already known to be sick” option, and T1T2 is used for “test and
treat if the individual is sick” option. In our model, T1 is treated differently than T1T2,
since in some cases the treatment may not exist, is expensive, is not very effective,
or may have side effects (in which case the patient might choose not to be treated).
Testing without treatment (T1) is a reasonable option (i.e., an improvement over not
testing) only if the awareness of the disease implies benefits other than treatment and
cure. These may include changes in utility, changes in probability of infecting others,
or changes in progression rates (see below). This also allows for partial treatments.
Furthermore, the action T2 allows the patient to delay his treatment. This can occur
when the patient cannot be treated immediately due to an existing health condition
or when a patient who did not want the treatment just after the test result changes
his mind later. We assume that the test results are immediately available and the
length of the treatment is negligible compared to the decision epoch. Hence, we
allow transitions to occur at the beginning of the decision epoch when a test and/or
treatment action is taken.
T = {0, . . . , N} is the set of (finite) decision epochs. Decision epochs can be years,
months or even days depending on the disease. In addition, the number of decision
epochs might change with respect to the problem. For example, when modeling
certain diseases, decisions are made every year (e.g., annual exams) and the number
of decision epochs is chosen to be an age after which an individual’s utility is negligible
while in other cases shorter time periods are desirable.
rt(s, a) is defined to be the utility of taking decision a in state s at decision
epoch t. It includes the QALYs of different health states and the cost associated
with the likelihood of infections to other people (if the disease under consideration
is infectious). The cost associated with infections would be primarily for secondary
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infections, since for many diseases this captures the majority of the reduction of
QALYs. It is also a standard way of including QALYs for diseases like HCV [114]
and HIV [84]. Finally, we assume that the costs of a test are only immediate costs
and that the test does not cause future harm to the individual. p(s′|s, a) denotes
the probability of going to state s′ from state s, when decision a is taken. The
non-stationary probability transitions are considered in the numerical results section.
Let π = {π0, . . . , πN} ∈ Π be a policy where Π denotes the set of all policies and
πt is the action at time t ∈ {0, . . . , N}. We assume πN = NT for all π ∈ Π. We
are interested in finding a policy that maximizes the total discounted expected utility









where 0 ≤ λ ≤ 1 is the discount factor. Let uπt (s) = rt(s, πt)+
∑
j∈S λp(j|s, πt)uπt+1(j).
In other words, uπt (s) is the total utility from decision epoch t onwards under policy
π if the system is in state s at that time. Let bπt (s) denote the probability that the
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In the remainder of this Chapter we study a special class of diseases with two
disease stages (in addition to healthy and death states). By considering this simpler
class of diseases, we are able to find closed-form expressions in terms of the problem
parameters that determine whether or not it is beneficial to test and/or treat the per-
son at a specific time. This type of Markov model might be appropriate for a disease
such as Chlamydia, which has earlier asymptomatic stage and a later symptomatic
stage in some patients.
The state space in this case is S = {(0, 0), (1, 0), (1, 1), (2, 1), (3, 0)}. State (0,0)
denotes the healthy state, state (3,0) denotes the death state, and the other states
represent the different stages of the disease as well as the awareness of the patient as
described previously. We assume that once the disease reaches stage 2, the individual
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is aware of it and the condition causes some irreversible damage (for example when







{NT, T1, T1T2} if s ∈ {(0, 0), (1, 0)},
{NT, T2} if s = (1, 1),
{NT} if s ∈ {(2, 1), (3, 0)}.
We assume that rt(s, a) = r(s, a) for all t ∈ {0, . . . , N}. We let r(s, NT ) = Rs,
and we subtract the cost of testing and/or treatment from this value whenever any
action other than NT is chosen. In other words, Rs denotes the utility of being in
state s when there are no testing and treatment costs. We let R(3,0) = 0, hence
uπt ((3, 0)) = 0, for all t ∈ {0, . . . , N} and π ∈ Π. Let c0 be the cost of testing, c1 be
the cost of treating the patient (in disease stage 1), v1 be the success probability of
the treatment (in disease stage 1). The elements of the probability transition matrix





pij if s = (i, 0), s
′ ∈ {(j, 0), (j, 1)},
qij if s = (i, 1), s
′ = (j, 1).
We assume that there is no direct transition to disease stage 2 from the healthy state.
The following lemma is used throughout the Chapter and its proof is immediate
from backwards induction.
Lemma 1. Let π and π′ be two policies that might differ after time t and agree
otherwise. If IE[uπt ] ≥ IE[uπ
′
t ], then IE[u
π
0 ] ≥ IE[uπ
′
0 ]. In other words, the policy that is
better at time t is a better policy.
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Let us define fi(x, y) for i ∈ {1, . . . , 6} and x1, x2 ∈ {0, . . . , N} as follows:
f1(x1, x2) = −c0
(px2−x100 (p11 − p00 − p01) + px2−x111 p01
p01(p
x2−x1




























f3(x1, x2) = f1(x1, x2) + f2(x1, x2),
f4(x1, x2) = −c0
(px2−x100 (p11 − p00 − p01) + px2−x111 p01
p01(p
x2−x1



























































f6(x1, x2) = f4(x1, x2) + f5(x1, x2).
The following theorems provide conditions for cost-effective testing and treatment
strategies when false negatives do not occur.
Theorem 1. If the individual was tested and/or treated at ti (where t0 = 0) for the
last time and awareness of the disease only affects the immediate utilities, then the
following strategy is cost-effective:
1. If he is healthy, or treated successfully at time ti, then it is cost-effective to test
him (and treat him if he is sick) at time ti+1 if f1(ti, ti+1) ≥ 0 (f3(ti, ti+1) ≥ 0).
2. If he is tested to be in disease stage 1 and the treatment is not successful (or
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he is not treated) at time ti, then it is cost-effective to treat him at time ti+1 if
f2(ti, ti+1) ≥ 0.
The proof is in the Appendix to this Chapter.
Theorem 2. If the individual was tested and/or treated at ti (where t0 = 0) for the
last time and awareness of the disease only affects the disease’s progression, then the
following strategy is cost-effective:
1. If he is healthy, or treated successfully at time ti, then it is cost-effective to test
him (and treat him if he is sick) at time ti+1 if f4(ti, ti+1) ≥ 0 (f6(ti, ti+1) ≥ 0).
2. If he is tested to be in disease stage 1 and the treatment is not successful (he
is not treated) at time ti, then it is cost-effective to treat him at time ti+1 if
f5(ti, ti+1) ≥ 0.
The proof is similar to the proof of Theorem 1, hence it is omitted. Theorems 1
and 2 show that if there exists a time t1 such that it is cost-effective to test(and/or
treat) the individual, assuming that there will be no other interventions later on, then
this action should be taken at time t1. Furthermore, if there exists a time t2 after
time t1 such that the intervention at time t2 is better than doing nothing, then this
intervention should be done as well. Similarly, at every ti+1, the decision is based on
the health state at the time of previous intervention and the remaining time until N .
Note that the previous theorems assumed that awareness of the disease either
affects the immediate rewards or the progression of the disease, and this is correct
for most of the diseases. We could simultaneously incorporate both changes into our
model, but for the sake of simplicity, these expressions were not provided here. The
next section considers a disease (HCV) where both progression and the immediate
rewards depend on the awareness of the disease.
Tests for diseases may result in false negatives or false positives. In this study, we
assume that a false positive is detected by a followup-up test with greater accuracy,
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which is the case in practice. False negatives are more complicated since the individual
is led t believe that he is healthy, when in fact he has the disease.
3.4 Application of the Model to HCV
Hepatitis C virus (HCV) is a blood-borne virus that typically leads to a slow progres-
sion of chronic liver disease. The majority of people are asymptomatic for decades
before the negative health effects first become noticeable. In the US, an estimated
3.9 million people are currently infected [25], making it the most common chronic
blood-borne infection in the country. HCV can cause liver cell damage, cancer, and
cirrhosis, and is the leading cause for liver transplants. Most people are unaware they
have the disease until they develop end stage liver disease but may spread the disease
to others even when they are asymptomatic. There is currently no vaccine for HCV,
although treatments exist that can cure with a 54% rate if applied early enough. The
high cost of treating the advanced disease, combined with the infectivity and long
asymptomatic period make HCV a candidate for screening programs.
Recall that Theorems 1 and 2 make the assumption that awareness of HCV in-
fection effects only the disease progression or the rewards. These restrictions are
only imposed for the sake of brevity. The theorems can be joined into one where the
progression and rewards can change simultaneously. However, since the expressions
become much more cumbersome, we omit them. For the computational results that
follow we use the results from Section 3.3.1 allowing disease progression and rewards
to change simultaneously. We populate the model with parameters specific to HCV.
The state space in this case is defined as:
• (0,0) = Healthy
• (1,0) = Infected (unaware)
• (1,1) = Infected (aware)
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• (2,1) = Decompensated cirrhosis including associated complications (hepatocel-
lular carcinoma, liver transplant)
• (3,0) = Death
This is a simplified natural history of the disease obtained from [7, 48, 57, 114]. We
develop a Monte Carlo simulation of the disease progression in MATLAB. Individuals
enter the system uninfected at age 15. We then implement the following testing
strategy: from ages 15-35, in each period, we check whether taking any action is cost-
effective. Whenever it is cost-effective to take an action, the respective action is taken
at that time (i.e. test, test and treat, treat, treat again). Ages 15-35 constitute the
decision epochs. After age 35, we add a final reward which represents the continued
disease progression (or lack thereof) until age 80 (or death) based on modified model
parameters that reflect a higher natural death rate and a lower incidence.
The model is based on QALYs and costs, which are associated with each health
state as summarized in Table 4. The utility in each period is calculated by converting
the QALY associated with that period to a cost where one QALY corresponds to
$50,000, and then subtracting the dollar costs of the screening test, treatment, and
annual HCV related health costs. The values for the transition probabilities were
taken from the literature. Some of the transitions depend greatly on the population
considered. For example, injection drug users (IDUs) are at higher risk for initially
acquiring HCV, while those who drink more than 50 grams of alcohol per day have
faster progression rates to decompensated cirrhosis. See Table 4 for the details on
the probabilities and rates. Whenever simplifications were made due to the nature of
the model contained herein, we used conservative estimates so that the results would
not be biased towards increased testing.
Due to limited HCV incidence data in the literature, it is difficult to assess the age
period during an individual’s life when they are susceptible to HCV. Therefore, since
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the HCV risk groups are very similar to that of HIV, we examined HIV incidence data
to extrapolate the ages at which individuals are at most risk for the overall population.
According to the Centers for Disease Control and Prevention (2005a), children under
age 13 constitute less than 1% of persons living with HIV through the year 2000
(mostly acquired through mother-to-infant transmission, which is not studied in this
model), and after age 55 HIV infection rates drop dramatically. According to the
Department of Health and Human Services (2005), percent drug use rises dramatically
from age range 12-13 to age range 14-15 and remains high until age range 50-54.
Consequently, we assume individuals are susceptible to HCV infection during the
entire time horizon of ages 15-35, making it a conservative assumption that does not
bias towards testing. Table 4 also indicates the probabilities of infection for each risk
group.
The cost of infecting others with HCV is calculated using the given data as the
additional total discounted lifetime cost of an individual as a result of acquiring HCV.
We do this by subtracting the total discounted cost of an individual with probability
of acquiring HCV equal to zero from the total discounted cost of an individual who
acquires HCV at age of 23 (since this data does not exist for HCV, the value is based
on the average age of HIV infection from [102] because they have similar behavioral
factors). Both calculations are made assuming no screening. The cost of infecting
others is thus calculated to be $50, 939, which is equivalent to a reduction of 1.1
QALYs in our model. The expected cost of a secondary infection must be multiplied
by the probability of infecting someone else at each time step, which will depend
greatly on the behavioral characteristics of the individual in question and his age.
Hence, we will assume that the probability of infecting others is identical to the
patient’s probability of acquiring HCV himself.
Most of the existing screening papers have not taken into account varying progres-
sions due to alcohol, although medical studies have found there can be a significant
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Table 4: Parameter values for model
Parameter Value Reference
Time Horizon of Decision ages 15-35 model assumption
Probability of Infection for IDU population 0.014 [28]
Probability of Infection for general population 0.0004 [25]
Probability of Infection after age 33 (all pops) 0 model assumption
Progression to decomp cirrhosis (alcohol) 0.0115 [136]
Progression to decomp cirrhosis (no alcohol) 0.0025 [136]
Death rate in decomp cirrhosis 0.22 [48]
Death rate due to other causes (ages 13-33) 0.0016 [23]
Death rate due to other causes (age > 33) 0.015 [23]
Probability of Treatment Success 54% [69]
% population heavy drinkers 4.9% [78]
Discount factor for QALYs 0.97 [114]
Discount factor for costs 0.97 [68]
Costs
Decompensated Cirrhosis 25,691 [122]
Test 24.42 [118]
Treatment 22,896 [40]
Secondary Infections 50,939 calculated from model
QALYs
Infected Aware 0.98 [114]
Disease Complications 0.48 [57]
effect. We define a person as a heavy drinker if he has 2 or more drinks per day
(greater than 50 grams of alcohol). We assume that once a person becomes aware
of his infection, he reduces his drinking below the 50 grams threshold (we also study
sensitivity to this factor), and he reduces his probability of infecting others by half
[114]. Behavioral change, then, not only affects the progression of the disease in a
patient, but also the rate of transmission to others.
Figure 5 and Table 5 show the average rewards obtained through the Monte Carlo
simulations using the aforementioned testing strategy. Several scenarios are consid-
ered including testing the overall and IDU populations under different alcohol and
test acceptance assumptions. In the case of the overall and IDU populations we
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assume 4.9% of the population drink excessively (estimated using the 2001-2004 Na-
tional Health and Nutrition Examination Survey) as the base case. Since it may
not be feasible to conduct an HCV test at the date specified by our testing strategy,
we also consider cases where there is a 70% chance of the test occurring when it is
cost-effective to do so. We refer to this scenario in the results as 70% test acceptance,
where we assume 4.9% of the population consumes alcohol excessively. We consider
cases where individuals who drink excessively and become aware of an HCV infec-
tion reduce alcohol consumption to less than 50 grams/day only 50% of the time,
rather than the base case of always reducing alcohol consumption. Finally, in the last
column, we consider only individuals who do not consume alcohol excessively.
Testing is never cost-effective for members of the overall population who do not
consume alcohol excessively or when there is a only 50% alcohol reduction, and con-
sequently the mean number of tests for those is 0 (as is the mean QALY gain and
cost). Testing occurs at age 20 and 25 for the overall population base case. When
we use a 70% acceptance rate and the first test is missed, the testing strategy then
recommends tests at age 21 and 26. If the test at age 21 is also missed, then the test-
ing recommends testing at age 22 only. For IDU population, testing is cost-effective
every year of the decision epochs (i.e., ages 16-35), regardless of whether any tests are
missed. It is clear from the figure that the largest QALY gains are a result of high
incidence and alcohol consumption.
The threshold incidence for testing (and treating when necessary) is 0.021% when
4.9% of the population consumes alcohol excessively. In that case testing becomes
cost-effective for age 27. When no excessive alcohol consumption is assumed, the


















Figure 5: Mean cost/QALY for the overall and IDU populations from implementing
the dynamic policy. Confidence intervals calculated using standard errors.
3.5 Conclusions
In this Chapter we have developed a Markov Decision Process (MDP) model for ex-
amining the timing of testing with treatment as an option where the action can result
in disease awareness that changes the progression of the disease, and the MDP has
partial updating of disease presence based on testing. In particular, we find sufficient
conditions for testing (and treating) to be cost beneficial from a societal perspec-
tive. We consider dynamical screening and treatment policies that are determined by
the result of the individual’s previous test result as well as disease’s progression and
infectivity characteristics.
We use the MDP model in the case of Hepatitis C to study the timing of test
and treatment actions for various populations. We use medical data to estimate the
progression of the disease, prevalence, health costs, and infectivity. We find that both
test-only and test-and-treat are cost-effective for IDU populations. The additional
QALYs gained as compared to no testing can be as high as 0.15 for test-and-treat for
IDUs. Regarding the general population, our recommendations find that testing and
treating meets the $50,000/QALY cost-effectiveness threshold, albeit not by much.
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Table 5: Results for the overall and IDU populations from implementing the dynamic
testing policy (standard errors are shown in parenthesis)
Overall population
Mean QALYs Mean Mean number
gained Cost of tests
Base case (4.9% Alcohol) 0.0026 (0.00027) 116.82 (3.1) 1.9826 (0.00026)
0.7 test accept rate 0.0028 (0.00026) 119.39 (3.2) 1.9701 (0.00032)
IDU Population
Base case (4.9% Alcohol) 0.1625 (0.0028) 3548.9 (42.4) 17.591 (0.0045)
0.7 test accept rate 0.1503 (0.0029) 3214.5 (40.9) 12.269 (0.0062)
50% alcohol reduction 0.1622 (0.0028 3551.1 (42.5) 17.591 (.0045)
No alcohol consumption 0.1401 (0.0023) 3663.6 (42.0) 17.591 (.0045)
We also find that incorporating behavior has an impact on recommendations, but
that the IDU population should be tested even if there are no behavioral changes from
awareness of having HCV. We also find that the number of actions tends to decrease
with the effectiveness of behavioral changes in drinking, and that the effectiveness of
alcohol behavior change can impact whether test-and-treat is better.
Our analysis also supports the CDC recommendations to test and treat groups
with high risk of acquiring HCV. The overall population group is not currently ad-
dressed by CDC recommendations since most analysis has not incorporated the effect
of alcohol behavior change on progression of Hepatitis C. We also add to the lit-
erature by specifying ages for testing of other populations. We have also studied
cost-effectiveness using cost minimization (including productivity losses) as the ob-
jective or examining the ratio of cost paid to utility gained, and we find similar
recommendations on which groups should be tested and how often.
For future work, it would be useful to apply our MDP for determining when to test
or treat to other diseases with different characteristics. The research also suggests
that examining dynamic screening policies (e.g., as in [38]) could be beneficial for




Proof of Theorem 1
Let π be a policy that satisfies πti+1 = NT for t > ti. Backwards induction shows
that

























































1. First, assume that the individual is healthy at time ti (either his test result
shows that he is healthy or he is treated successfully). We will compare the
policies π and π′, where π′t = πt for t ≤ ti, π′ti+1 = T , π′t = NT for t > ti and












((2, 1)) = uπti+1((2, 1)).
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Some algebra shows that IE[uπ
′
ti+1
] ≥ IE[uπti+1] if f1(ti, ti+1) ≥ 0. Since π and π′
agree before time ti+1, Lemma 1 shows that IE[u
π′
0 ] ≥ IE[uπ0 ].
Similarly, we compare two policies π and π′′, where π′′t = πt for t ≤ ti, π′′ti+1 =
T1T2, π
′′
















((2, 1)) = uπti+1((2, 1)).
We then find the expected values of utility-to-go functions as above and some
algebra shows that IE[uπ
′′
ti+1
] ≥ IE[uπti+1] if f3(ti, ti+1) ≥ 0. Since π and π′′ agree
before time ti+1, Lemma 1 shows that IE[u
π′′
0 ] ≥ IE[uπ0 ].
2. We compare two policies π and π′′′, where π′′′t = πt for t ≤ ti, π′′′ti+1 = T2,











((2, 1)) = uπti+1((2, 1)).
Some algebra shows that IE[uπ
′′′
ti+1
] ≥ IE[uπti+1] if f2(ti, ti+1) ≥ 0. Since π and π′′′
agree before time ti+1, Lemma 1 shows that IE[u
π′′′
0 ] ≥ IE[uπ0 ].
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Next, we generalize our results to include the case when false negatives may occur
Specifically, let n1 denote the probability that the test result is negative when the
person’s health state is 1. In this case, closed form expressions can be obtained but
they are quite complicated, hence we will simply give the solution methodology for
different cases.
1. If the person’s test result is negative at time ti and he has not been tested since





























Now, let us compare two policies π and π′, where πt = π
′
t for t ≤ ti, πti+1 = NT ,
π′ti+1 = T1, πt = π
′
t = NT for t > ti and t 6= ti+1. uπt (s) are the same as in
















((2, 1)) = uπti+1((2, 1)).























































and the utility-to-go function for π′ can be calculated similarly. Then, we can
find a condition which guarantees that IE[uπ
′
ti+1
] ≥ IE[uπti+1 ] will hold.
Similarly, if the test result at time ti indicates that he is healthy and we want
to compare two policies π and π′′, where πt = π
′′
t for t ≤ ti, πti+1 = NT ,
π′′ti+1 = T1T2, πt = π
′′
t = NT for t > ti and t 6= ti+1. uπti+1(s) are as in the proof






















((2, 1)) = uπti+1((2, 1)).




] ≥ IE[uπti+1 ] will hold.
2. If the individual is tested and found to be in disease stage 1 and the treatment
is successful, then this case is the similar to the previous case, assuming that
after the treatment, individual’s health state can be determined accurately. We
use bπti((0, 0)) = 1, and b
π
ti
((1, 0)) = 0 when finding the expected utility-to-go
functions and otherwise proceed as above.
3. If the individual is tested and found to be in disease stage 1 and the treatment
is not successful (or he is not treated) at time ti, then this case is similar to the




TESTING FOR HEPATITIS C VIRUS: IMPLICATIONS
FOR POLICY
4.1 Introduction
Hepatitis C virus (HCV) is a blood-borne disease present in 3.9 million people in the
US (48% are unaware) that can cause end stage liver disease [25]. It is the leading
cause for liver transplants and the 10th leading cause of death in the US. It is generally
asymptomatic for decades, and many people are unaware of the presence of the disease
until end stage liver disease begins and treatment is no longer effective. HCV can
be transmitted during the asymptomatic period. There is currently no vaccine, and
treatments are somewhat effective if caught early enough. Once infected about 85%
will go on to chronic HCV which leads to liver cirrhosis in over 20% of patients [79].
The risk of hepatocellular carcinoma is 17 times higher in patients with HCV [42].
8,000 to 10,000 deaths per year in the U.S. are attributed to chronic liver disease,
40-60% of which are caused by HCV [21]. Prevalence in the overall population is 2%
and as high as 40-60% in injection drug users, which is twice that for HIV. [28].
Several researchers have used models to assess the cost-effectiveness of treatment
of HCV. The general consensus is that peginterferon therapy with ribavirin is cost-
effective in treating individuals who are known to have HCV [57, 112, 138, 7]. There is
far less consensus on the literature regarding testing for HCV. For example, Casteln-
uovo [14] finds that testing is cost-effective for injection drug users based on a decision
analytic model; Gordon [54] also reports that testing can be cost-effective for high-
risk groups. However, Plunkett [96] finds that screening of asymptomatic pregnant
women for HCV infection is not cost-effective, even when the benefits to the child are
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considered. In addition, Pereira [91] used a Markov simulation model to show that
testing blood donors for HCV was cost-saving for the health care system. Finally,
Singer [114] found that routine HCV testing was not cost-effective in asymptomatic,
average-risk adults using a Monte Carlo Markov Simulation where the age of testing
was assumed a priori, albeit assuming an older treatment than today’s standard.
There is also little consensus among public health agencies on testing recommen-
dations. For example, the US Public Health Service (USPHS) and Infectious Diseases
Society of America (IDSA) recommend testing HIV positive persons for HCV. The
US Preventive Services Task Force (USPSTF) recommends against routine testing for
HCV in the general population and does not make a recommendation for at risk pop-
ulation. The Centers for Disease Control and Prevention (CDC), on the other hand,
does recommend routine testing for population groups with a high risk for acquiring
HCV such as drug users or commercial sex workers.
Awareness of HCV can effect the disease progression (by reducing alcohol con-
sumption, if any) and potentially reduce secondary infections. Neither the literature
on cost-effectiveness for screening of HCV nor the public health agencies make rec-
ommendations about timing of testing. The explicit consideration of timing is impor-
tant, not only because it reveals the best time to test, but also because it could alter
whether or not testing is cost-effective in the first place. The aim of this Chapter is
to determine whether (and when) it is cost-effective to test and treat HCV, and to
evaluate the best ages for testing.
4.2 Materials and Methods
We develop a Markov model of the natural history of Hepatitis C infection following
those of Bennett [7], Singer [114], Stein [118], and Hornberger [57]. The states of the
Markov chain are displayed in Figure 6, and the transition probabilities are listed
















Figure 6: The states of HCV where solid lines represent natural history transitions
and dashed lines represent transitions due to treatment success. Not shown in the
diagram but included in the model are transitions to death from all states due to
causes other than HCV.
life he or she will transition to another health state or remain in the same state.
Each individual begins uninfected at age 13 and may or may not acquire HCV in
the following years of life. Transition probabilities vary according to age, risk group,
alcohol consumption, and awareness of HCV status. Each health state has an associ-
ated annual cost and utility measured in quality adjusted life years which are listed
in Table 7. We discount the costs and QALY’s by 3% [114] and compute the total
discounted lifetime cost and QALYs of individuals with and without testing. All costs
and QALYs are discounted to age 13 which represents the first period of the model.
We allow possibility of false positives and negatives. When a true positive is
detected the individual will decrease his transmission to others by half, reduce alcohol
consumption to less than 50 grams per day (if previously drinking greater than 50
grams per day), and begin treatment in the same year (if eligible as determined by
the probability in Table 10).
We assume the treatment for all patients to be peginterferon plus ribavirin which is
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the current most cost-effective and successful treatment for HCV. We include the pos-
sibility of individuals quitting treatment without completing it, as well as accounting
for the percentage of people ineligible for treatment all together due to contraindi-
cations or other reasons. We account for the different success rates of treatments
based on genotype, and include a probability of individuals being of each genotype.
When treatment is not successful, and/or the individual drops out of treatment early,
the individual continues through the natural history of HCV. When the treatment is
successful, the individual is then assumed uninfected and still susceptible to acquiring
HCV in the future.
Tables 7 - 10 lists the various assumptions and values used in the model. When
there does not exist a consensus in the literature for a parameter value, we choose
conservative estimates. For example, Chong [31] cites several different utility values
for the health states of individuals with HCV used in previous papers; some derived
from patient survey and others from expert elicitation. In our base case analysis we
chose QALY values from Singer which are the most conservative, (i.e., higher QALY
values for each state than other studies). We also choose a conservative estimate for
the effect alcohol has on progression to cirrhosis (Freeman [51] versus Poynard [98]).
Consequently, our results are not biased towards screening.
The model was written in Matlab 6.5 and run on a computing cluster with nodes
that contain two 2.4GHz Xeon processors and 2GB RAM each.
4.3 Results
We considered up to 5 tests per lifetime in our analysis. Tests at all age combinations
were considered with a minimum of two years between tests. We report the results
of the model using additional discounted cost and additional discounted QALYs re-
sulting from the testing policy.
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Table 6: Parameter values for transition probabilities (reported in annual terms)
Base case transition probabilities Value References
Progression rate to Compensated Cirrhosis 0.0072 [51]
for heavy drinkers
Progression rate to Compensated Cirrhosis 0.0036 [98]
without heavy drinking
Progression rate to Decompensated Cirrhosis 0.0390 [7]
Progression rate to HCC 0.0268 [36]
from Cirrhosis or Decompensated Cirrhosis
Rate of liver transplant 0.0300 [7]
from Decompensated Cirrhosis
Death rate from Decompensated Cirrhosis 0.2180 [48]
Death rate from HCC 0.4270 [48],
[7]
Death rate after liver transplant first year 0.1370 [50]
Death rate after liver transplant after first year 0.0520 [50]
Death rate from other causes [23]
4.3.1 Overall Population
Our results indicate that it costs less than $50,000/QALY to test (and possibly treat)
members of the overall population for HCV during ages 20-51. These results show
that the timing of HCV testing is important in determining its cost-effectiveness. It is
never cost-effective to test only (without treatment) for the overall population. The
test age that results in the highest additional QALYs is 33. This age balances the
tradeoffs of testing later to decrease the likelihood of testing before infection occurs
while testing early enough so that treatment is still effective and more secondary
infections can be averted.
Figure 7 is a plot of the additional discounted QALYs gained versus the additional
discounted cost for testing the overall population at various ages. Points below the
$50K/QALY line represent ages at which it is cost-effective to test. The results are
shown for three scenarios: the base case (where anyone who drinks more than 50
grams of alcohol per day reduces consumption to less than 50 grams per day after a
positive HCV test), under the assumption that no one reduces alcohol consumption
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Table 7: QALY values for various health states
Health State QALY Value Reference
Uninfected 1.00 [114]
Infected without Cirrhosis 0.96 [114]
Compensated Cirrhosis 0.80 [114]
Decompensated Cirrhosis 0.56 [114]
Transplantation (1st year) 0.80 [114]
Transplantation (after 1st year) 0.95 [114]
Hepatocellular Carcinoma 0.25 [114]
Treatment 0.93 [7]
Table 8: Annual probability of HCV infection by type of risk group
Risk Group Annual Probability References
of Infection
Overall population 0.0004 [25]
Injection drug users 0.014 [28]
Incarcerated individuals 0.0016 [28]
Commercial sex workers 0.0012 [80]
STD clinic attendees (non-IDU) 0.0008 [80]
following an HCV test, and when only patients with genotype 2 are treated for HCV.
The ages corresponding to each point are listed only for the base case. The cost-
effective age range for various populations, including those shown in Figure 7, are
displayed in Table 14.
Figure 8 shows the results of one and two tests per lifetime for the overall pop-
ulation. Each dark blue point represents the additional cost and additional QALYs
resulting from a test at the specified age. We can see that testing between ages 20 and
51 results in a cost/QALY smaller than $50,000/QALY. Each light blue point repre-
sents the additional cost and additional QALYs resulting from some two test policy
(compared to no testing at all) where the ages are not listed on the figure. Table
11 lists the policies in which the second test is incrementally cost-effective given the
first test. This table can be used for an individual that has already had an HCV test
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Table 9: Costs and discount value (where costs are in 2000 dollars)
Parameter Value References
Cost of screening test (ELISA) $ 24.42 [118]
Cost of combination therapy $ 22,896 [40]
(peginterferon + ribavirin)
Discount factor for costs 3% [68]
Discount factor for QALYs 3% [114]
Health State
Compensated Cirrhosis $ 494 / year [122]
Decompensated Cirrhosis $ 25,691 / year [122]
Transplantation (1st year) $ 312,804 / year [122]
Transplantation (after 1st year) $ 30,121 / year [122]
Hepatocellular Carcinoma $ 16,748 / year [122]
Table 10: Genotype, testing, and infection values
Factor Value Reference
Percent of population that is Genotype 1 (G1) 60% [57]
Treatment success rate for G1 29% [57]
Treatment success rate for non-Genotype 1 (G2) 62% [57]
Probability of ELISA test false negative 0.014 [114]
Probability of ELISA test false positive 0.009 [114]
QALY change from infecting others -1.1 calculated by model
Percent of population of heavy drinkers 4.90% [78]
and is interested in whether or not a testing at another age would be incrementally
cost-effective. However, it is important to note that Table 11 does not suggest that
the policies listed in it are the best two test policies. When multi-test policies are
considered as one single intervention, rather than multiple interventions at different
ages, we can find the policies that produce the maximum QALY gained while still
being cost-effective overall. These results are listed in Table 12.
Table 12 also shows the incremental cost-effectiveness of multiple tests. Since there
are many policies that are cost-effective, we pick the single test policy that results in
the highest QALYs and compare it to the two test policy with the highest QALYs
(only policies that are cost-effective according to the $50,000/QALY threshold are
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Overall Population 































































Figure 7: Cost versus QALY for one test policies of the overall population under
various assumption.
considered). Table 12 displays the incremental cost-effectiveness of adding additional
tests in this way for both the overall and the IDU populations.
4.3.2 At Risk Populations
Populations at risk for acquiring HCV have even wider age ranges for which single
testing is cost-effective. Table 13 indicates the age ranges for testing only and testing
with possible treatment various risk groups. For the riskiest group, injection drug
users, the single test cost-effective age range is 15-73 for those that drink more than 50
grams of alcohol per day, and 16-54 for those who drink less than 50 grams of alcohol
per day. The single test age yielding the highest QALYs is 32 and 35, respectively,
yielding $1,950.29/QALY and $16,954.84/QALY, respectively. In fact, testing alone
(without treatment) is itself cost savings for all ages greater than 15 for alcohol
drinkers and from 16-50 for non-alcohol drinkers.
Figure 9 shows the results for testing IDU’s that drink more than 50 grams/day





















































One Test + Treat
One Test Only
Two Test + Treat
50K/QALY line
Figure 8: Cost versus QALY for one and two test policies.
up to five tests per lifetime are displayed. One can see diminishing returns for higher
number of tests, but a reasonable increase in QALYs for a modest increase in cost.
Since there are far too many policies to explicitly list, we indicate the testing ages of
the policies that result in the highest QALYs for each of 1-5 tests per lifetime. We
also indicate the testing ages of policies on the efficient frontier (i.e., policies that
result in highest QALYs for least cost) at the points where the frontier changes from
1 test to 2 tests per lifetime, 2 to 3 tests per lifetime, etc. We also indicate the testing
ages of one of the poorer policies that results in fewer QALYs gained at higher cost.
While the vast majority of policies are cost-effective, beginning the first test early
and spacing out the tests during the lifetime is most efficient. Virtually all age
combinations where the ages fall within the single test cost-effectiveness age range are
also cost-effective. Since it may be difficult to obtain IDU’s for testing, a reasonable
policy would be to test an IDU whenever given the opportunity, even if they’ve had
previous tests. Ideally, however, the tests should be reasonably spaced apart so that
the policy lies closer to the efficient frontier. The resulting cost and QALYs depend
on several factors including the spacing between tests, the number of tests, and the
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Table 11: Incrementally cost-effective two test policies for testing the overall popu-
lation for HCV
Two test policies where first and second tests
are Incrementally cost-effective (ICE)
first test age, second test age ICE of first test ICE of second test
second test age range with best ICE with best ICE
20, 28-49 37 $46,631 $42,448
21, 30-49 37 $43,989 $43,506
22, 31-48 38 $42,001 $44,585
23, 33-47 39 $40,480 $45,722
24, 35-47 40 $39,306 $46,915
25, 37-45 41 $38,395 $48,171
26, 39-44 41 $37,693 $49,466
age of the first test. However, one can see from the multi-test policies that result in
the highest QALYs that policies in which the tests are somewhat centered around
age 32 and fall within the single test cost-effective age range are quite efficient.
From Table 13 we can see that for the several at-risk populations the testing age
resulting in highest QALYs is near 32 for those that drink more than 50 grams of
alcohol per day, and near 35 for those who do not. The principle of centering the tests
around this age while stilling falling within the single test cost-effective age range also
holds and results in very cost-effective testing policies.
4.4 Sensitivity Analysis
Our estimate of incidence of HCV in the overall population does not include those
that acquired HCV through a blood transfusion prior to 1992. However, we also
ran the model with values for incidence that does include transfusion related HCV
infection because many of those infections are found decades later. We found that
the results change very little due to the fact that the number of people that have
had transfusions prior to 1992 is very small compared to the total population. By
including those with transfusions, however, the cost-effective single test age range
changes to 19-52.
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Table 12: Multiple tests per lifetime for testing the overall on IDU populations for
HCV
For each number of tests, the policy with the highest QALY’s is listed
Overall Population
1 test 2 tests 3 tests 4 tests 5 tests
Test Ages 33 26,44 23,35,51 21,31,41,55 19,25,33,43,55
Cost-effectiveness
($/QALY) $36,340 $41,958 $46,883 $51,464 $57,425
Incremental
cost-effectiveness $57,008 $82,516 $115,891 $202,482
IDU Alcohol Population
Test Ages 32 26,41 23,33,47 21,29,37,49 19,25,31,39,49
Cost-effectiveness
($/QALY) $1,950 $2,458 $2,859 $2,894 $2,822
Incremental
cost-effectiveness
We also found that reducing the incidence of the overall population by a factor
of 2.5 (i.e., 0.016%) was just enough to cause testing (with possible treatment) to no
longer be cost-effective at any age. When the probability of acquiring HCV reaches
0.0595%, testing only starts to become cost-effective (at age 41 only)
There is also some concern over the disutility of awareness of an HCV infection
due to psychological harm. Our model indicates that only if the cost of this harm
exceeds $4,850 is testing (and possibly treating) the overall population no longer cost-
effective for any age. Moreover, if the cost of the HCV test increases by at least an
additional $38 (or if the disutility of taking a test equates to $38), then testing (and
possibly treating) the overall population is no longer cost-effective for any age.
Table 14 highlights the results of the model using other values for various param-
eters. The first column represents the parameter that is being changed from the base
case. The second column represents the single test policy that results in the highest
QALYs. The third column represents the single test+treat policy that results in the
highest QALYs. Finally, the last column represents the cost/QALY of the policy
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Figure 9: Cost versus QALY of up to 5 tests per lifetime for the IDU population .
in the previous column. The table shows results for various changes of the parame-
ter values, including using more liberal estimates of the effect of alcohol and quality
adjusted life years.
4.5 Discussion
Our results show that when determining the cost-effectiveness of HCV testing, con-
sidering timing and the effect of alcohol on disease progression are critical. If we
ignore the effect of alcohol, and average the costs and QALYs of testing over all of
the ages considered, then testing for HCV is no longer cost-effective, with or without
treatment. However, when we explicitly consider the ages and the effects of alcohol,
we see that testing the overall population for HCV is indeed cost-effective for many
ages.
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Our results differ from Singer that state that testing the overall population is not
cost-effective, however Singer’s analysis did not include the effect of alcohol and was
conducted when there was no available data on peginterferon therapy. Consequently,
interferon therapy (plus ribavirin) was the assumed treatment, which has a much
higher rate of ineligibility (80%) [114]. Singer states that the model is sensitive to
this value, and that when 50% of the population is eligible for treatment, then testing
the overall population is cost-effective. Since our analysis assumes 50% ineligibility
for peginterferon therapy (plus ribavirin) based on [60, 101], our results agree with
Singer in this regard. Under Singer’s assumptions on treatment (i.e., cost, treatment
success rate, % ineligible), and without including the effect of alcohol, our model
agrees with Singer’s result that it is not cost-effective to test the overall population
at any age for HCV. However, even under the treatment assumptions from Singer,
when 4.9% of the population drinks greater than 50 grams of alcohol per day (and
reduce this consumption to less than 50 grams per day following a positive HCV test)
our model suggests that it is cost-effective to test the overall population between ages
30 - 40, while using the conservative estimates on the effect of alcohol from Freeman
[51].
Our results are in agreement with the CDC recommendations for high risk groups
(although these do not explicitly consider age, frequency or alcohol). Our results ad-
ditionally indicate, however, that testing (and treating) the overall population is also
cost-effective for several ages. This result disagrees with the U.S. Preventive Services
Task Force (USPSTF) which recommends against testing the overall population and
makes no recommendation for high risk groups. The USPSTF believes that the “psy-
chological harm” of screening such as anxiety or the impact on partner relationships
can be an important factor. In addition, they argue that the natural progression of
HCV is unclear in that treatment is only effective for a subset of the population and
it is difficult to determine who these individuals are a priori. We do explicitly model
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the disutility to the individual of ineffective treatment, though we did not explicitly
consider the potential psychological harm from the screening process since there are
not good estimates of this cost for HCV. We considered this issue in sensitivity anal-
ysis and found the dollar value that would be necessary to make testing no longer
cost-effective. It is noteworthy that the anxiety of a positive test would be greater
for HIV for which universal screening is recommended. Additionally, for an infectious
disease that can lead to death, averting secondary infections must also be a primary
consideration.
Our results indicate that for high risk groups, more than one test per lifetime
may be the best policy. We found that centering the testing ages around age 32
results in the highest QALYs gained when testing begins in early twenties and ends
in late forties. Our sensitivity analysis shows that our results are robust under our
assumptions.
New HCV testing technologies are being developed that could impact the recom-
mendation regarding universal screening. OraSure Technologies Inc. (www.orasure.com)
is commercializing a rapid HCV test that uses a saliva sample, which should bring
down costs and be easier to administer.
Is is noteworthy to recall that the conclusion that it is cost-effective to test the
overall population for HCV is made from a public health or societal perspective. That
is, a particular insurance company or medical practice may have different incentives
and may or may not find it in their best interest to test for HCV. Many of the benefits
of an HCV test are realized several years, perhaps decades, later. Consequently, the
insurance company that pays for an individual’s HCV test may not be the same
one that receives the benefits of the test (in averted health costs). Indeed, this
unfortunate misalignment of incentives regarding health outcomes and costs is true
for many medical interventions. Fortunately, other incentives exist for insurance
companies to reimburse expenditures associated with interventions that are regarded
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as cost-effective (from a societal perspective) by the medical community.
Limitations of our model include the fact that we do not include productivity
losses from morbidity/mortality (but we do include death rates from other causes).
Consequently, our results are a conservative estimate. Due to limited availability of
data, we use the same drop out and ineligibility rates for all populations, however,
we again use conservative estimates. Lastly, the age ranges for increased probability
of infection for high risk groups were taken from HIV data since it is not available for
HCV. Because the viruses are transmitted through similar means we feel this estimate
is reasonable. Our sensitivity analysis shows that the model is not sensitive to these
values.
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Table 13: Results for testing various groups at risk for HCV. CSW = Commercial Sex Workers. CE = cost-effectiveness.
Population Sub-population 1 test 1 test+treat 1 test+treat with $/QALY for single test
/Parameter CE ages CE ages highest QALY w/ highest QALY
Overall drink > 50 grams
alcohol / day >15 15-71 31 $9,047.97
Overall drink < 50 grams
alcohol / day empty 22-48 34 $40,996.62
Overall 4.9% drink > 50
grams alcohol / day empty 20-51 33 $36,340.09
CSW drink > 50 grams
alcohol / day >15 15-72 32 $6,702.86
CSW drink < 50 grams
alcohol / day empty 17-52 35 $34,474.00
CSW 4.9% drink > 50
grams alcohol / day empty 17-55 34 $30,148.82
Incarcerated 4.9% drink > 50
grams alcohol / day 19-66 15-55 33 $27,522.30
IDU drink > 50 grams
alcohol / day 15-80 15-73 32 $1,950.29
IDU drink < 50 grams
alcohol / day 16-50 16-54 35 $16,954.84
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Table 14: Sensitivity analysis for testing the overall population for HCV. CE =
cost-effective
Sub-population 1 test+treat 1 test+treat $/QALY for
/Parameter CE ages with highest single test w/
QALY highest QALY
No Alcohol
Reduction 21-49 34 $39,804.28
Treat Genotype
2 Only 21-59 33 $30,480.54
Infect age
start = 20 29-49 39 $42,984.19
Infect age
end = 45 20-51 33 $36,597.72
Cost of treatment
× 0.75 19-56 33 $31,455.21
Poynard [98] Alcohol
progression value 17-58 33 $27,177.07
QALY values
from Shiell [110] 18-59 34 $30,649.01
Progression to
Cirrhosis × 0.75 20-51 33 $36,340.09
Progression to Decomp.
Cirrhosis × 0.75 20-51 34 $37,709.55
Progression to
HCC × 0.75 20-51 33 $37,051.31
Progression to Liver
Transplant × 0.75 20-51 33 $36,443.38
Treatment failure
rate × 0.75 17-61 33 $26,368.78
Probability of
Infection × 0.4 empty 33 $50,899.45
Drop out rate × 2 22-46 33 $41,369.50
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CHAPTER V
BIAS IN MARKOV MODELS OF DISEASES
5.1 Introduction
Markov models are commonly used to simulate diseases when evaluating various med-
ical interventions. Modeling diseases allows us to consider long term consequences
and other implications not practical via clinical trials. Examples include an analysis
of cost-effectiveness of expanded HIV screening in the US[108, 84], an analysis of
the optimal age of vaccination[6], the optimal timing of liver transplantation[2, 3],
and an analysis of dynamic multi-drug therapies for HIV[133]. Markov models are
also used to forecast and estimate future morbidity, mortality, prevalence, and costs
of various diseases[138]. Markov models of diseases are often coupled with clinical
trial data to determine the cost-effectiveness of medical interventions. Given the lim-
ited amount of resources available, Markov models of diseases can potentially be a
relatively inexpensive, yet powerful tool to evaluate medical interventions.
However, due to limited disease data or model complexity, simplifying assumptions
are made in many Markov disease models. In this Chapter, we analyze the effect
of a common simplification, namely, that of modeling diseases that have nonlinear
progression with Markov models that assume constant progression. The assumption
of constant disease progression is used in many disease studies [4, 5, 35, 47, 51, 57, 64,
106, 114]. Studies often assume constant disease progression when there is insufficient
patient data to characterize non-linearities or changes over time. Constant progression
is also often assumed in order to reduce the model’s complexity, particularly when
deriving analytical results. In Chapter 3, for example, we used a reduced the state
space model of Hepatitis C for analytical tractability. Consequently, the model did
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Figure 10: METAVIR standard for liver disease progression.
not allow for disease progression to change as a function of disease severity. The
reduced state space was necessary to construct a dynamic policy of testing for the
disease.
When constant disease progression is assumed, caution must be exercised in order
to ensure that the disease progression is not overestimated or underestimated, which
we call bias. This Chapter explores bias in Markov models of disease when constant
disease progression is assumed. We consider diseases in which the progression (i.e.,
transition probabilities) depends on the severity of the disease (i.e., state) and diseases
in which progression varies with time (i.e., age, time spent in a state). In both
cases, we use Markov models and compare the use of state/time dependent transition
probabilities with the use of transition probabilities that assume constant progression
by aggregating data. We make such a comparison in order to determine if, and
under what conditions, Markov models that assume linear progression underestimate
or overestimate disease progression. We then use medical data to we assess the
magnitude of the bias for Hepatitis C (HCV), Alzheimer’s disease (AD), and lung
cancer.
5.2 Markov Models of Various Diseases
For Markov disease progression models that have state dependent transition probabil-
ities, we consider models of the type in Figure 10 and compare it to the case where the
71
probability transitions between states are not identical. Figure 10 is a standard disease
progression model used for liver disease that uses the METAVIR standard for liver
disease, which is the motivating disease for this analysis [57, 107, 114]. METAVIR
is a scoring system specifically designed for HCV patients in which the scores F0-
F4 represent different degrees of liver fibrosis. F0 represents no liver scarring and
F4 represent cirrhosis or advanced liver scarring; the states in between represent in-
termediate levels of liver damage. Patients are determined to be in one of the five
METAVIR states via a liver biopsy. Each state in Figure 10 corresponds to a score
on the METAVIR system, which are ordered by increasing liver damage. The x val-
ues in the figure are determined by diving the time since infection by the number of
states progressed during that time, and averaging over many patients. For example,
if a patient is determined to be in state F3 (as determined by a liver biopsy) with
an infection length of 30 years, the rate of liver disease progression is thus 3/30 =
0.1, which is then assumed to be the constant rate of progression between all states.
Consequently, the transition probabilities are identical by construction. This method
of arriving at a single aggregate transition probability is referred to as the indirect
method and is used in the majority of studies analyzing progression rates of HCV
[97, 145, 146]. We will refer to the value computed using the indirect method as the
indirect value.
When few patients in a data set have serial biopsies (i.e., biopsies at different
points in time for the same patient), the modeler has little choice but to use the
indirect method to estimate transition probabilities and implicitly assume constant
disease progression. However, when patient data with serial biopsies is available,
the modeler can potentially estimate the transition probabilities between METAVIR
states so that the disease progression is not assumed to be constant. This Chapter
provides insight into the value of having richer disease data (i.e., serial biopsies)
Studies involving liver disease progression typically assume a constant progression
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of liver disease [51, 57, 114] as described above. Few studies allow for state dependent
liver disease progression such as [7]. Studies have shown, however, that liver disease
progression is not constant and varies significantly between METAVIR states [71, 98,
113, 145]. Matsumura [71] and Yi, et al, [145] computed estimates for the transition
probabilities between the METAVIR states using patient data with serial biopsies.
Both studies also compute the x value using the indirect method. No studies have
analyzed, however, the consequences of using the single transition probability value
that assumes constant progression versus using the transition probabilities that vary
between states. Our study analyzes this question.
Many diseases are modeled by similar Markov chains to that of Figure 10, partic-
ulary those where the disease states represent scores on an ordinal rating system such
as the METAVIR standard. These diseases range from Alzheimer’s disease (AD) to
Glaucoma to Amyotrophic Lateral Sclerosis (ALS, also referred to as Lou Gehrig’s
Disease). These diseases are progressive, sometimes degenerative, diseases that may
or may not be fatal. The severity of AD, for example, is commonly ranked using
the Mini-Mental State Examination (MMSE) which is based on a scale of 0-30. The
Alzheimer’s Disease Assessment Scale and the Blessed Information Memory Concen-
tration are other common, ordered rating systems for Alzheimer’s disease. In practice,
the states are typically grouped to represent states such as “healthy,” “mild,” “mod-
erate,” and “severe.”
The majority of studies of AD assume a constant progression rate and use the same
single transition value between states of different severity [5, 35, 47, 64, 106]. Studies
that analyze the effect of different medical interventions on AD typically measure the
degree to which the intervention decreases the constant progression rate. Jonsson
[59], for example, determined that treatment with donepezil 5 mg corresponds to
multiplying the transition probability to a state with a lower MMSE score by (1 -
0.4636) and by (1 - 0.4807) for treatment with donepezil 10 mg. Studies have shown,
73
however, that the progression is far from constant and is typically slower in less severe
states [52, 119, 121]. Accordingly, some studies do use state dependent transition
probabilities [120, 121]. Like in the case of HCV, studies have not considered the
consequences of using the single transition probability value that assumes constant
progression versus using the transition probabilities that vary between states.
Another example of a disease that can be modeled by a Markov chain similar to
Figure 10 is the progression of ALS, which is often scored on a scale of 1-5 (Mild,
Moderate, Severe, Terminal, Death) [124]. Progression is often modeled as constant
over time [4]. Similar to the previous examples, studies have shown, however, that
ALS has nonlinear progression [124].
For Markov disease progression models that have time dependent transition prob-
abilities, we consider models of the type in Figures 11(a) and 11(b). In this case, we
can interpret states 1-N in Figure 11(b) as ages or as time spent in a risk state. The
former is appropriate to model diseases that progress faster with age such as HCV
or AD; the latter is appropriate to model diseases such as lung cancer whose risk
of occurrence increases with the number of years of smoking. The model in Figure
11(b) allows for the transitions to vary with time since the a′is can each have different
values, whereas the model in Figure 11(a) does not capture the time dependency and
is equivalent to constraining the a′is to be identical in Figure 11(b). Scherrer [109]
began a framework for analyzing bias in models with time dependent transition prob-
abilities and compared the two models in the case of two risk states plus a disease
state for two time periods where the disease state is an absorbing state.
Scherrer showed that the single transition probability of moving from the risk state
to the disease state obtained by averaging the true transition probabilities of many
risk states underestimates the likelihood of ending up in the disease state (when the
probability of transitioning to the disease state increases with time spent in the risk
state, and the entire population begins in the risk state). Scherrer also showed that
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(a) constant transition probabilities
(b) time dependent transition probabilities
Figure 11: Markov models for a disease with time dependent transition probabilities.
the result also holds when the population is initially evenly split between the two risk
states. We modify the Markov model in Scherrer (while preserving the characteristics
that cause bias) so that we can solve for a stationary distribution for n risk states
and arrive at conditions for bias that holds for the Markov model in steady state (i.e.,
independent of the initial population distribution).
Markov models with time dependent transition probabilities of the type in Figure
11(b) are appropriate for many other diseases where the transitions vary over time
or by age, including HCV, AD, lung cancer, cardiovascular disease and diabetes.
In the case of HCV, many studies utilize transition probabilities that vary by age
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(a) transition probabilities are constant
(b) transition probabilities are state dependent
Figure 12: Markov model for a disease with state dependent transition probabilities
as used in Monte Carlo simulations.
[57, 96, 123], whereas many others only use a single transition probability that applies
for all ages [114, 118] thereby not capturing the large differences in progression by
age. Our analysis studies the difference in the expected time to progress through the
METAVIR states of the HCV model using the single transition probability versus
using age dependent transition probabilities.
This model can also be used to capture incidence rates of diseases that vary with
time. For example, incidence of AD increases with age [93]; in this case, each age of
person’s life can represent a Markov state and can have a different transition rate to
the disease state. Similarly, since the probability of acquiring lung cancer increases
with the number of years of smoking [127], the Markov states can represent the
number of years of smoking, each with different transition rates to lung cancer.
5.3 Monte Carlo Simulations of Markov Models of Dis-
eases
A common method of analyzing Markov chains of disease progression in the medical
literature is to employ the use of Monte Carlo simulations [84, 108, 114]. In these
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models, each individual patient’s clinical course is followed from the time of entry
into the model until death or the final state of interest is reached. A running tally
is kept of the amount of time spent in each health state including the associated
costs and quality adjusted life years (which measures the benefits gained). Upon
the patient’s death (or arrival in the final state), the next patient is introduced into
the model. The process repeats over a large number of patients and the results are
averaged over all patients. Figure 12(a) graphically represents the scenario where
we require the transition probabilities for the disease progression to be identical in a
Monte Carlo simulation, and we have generalized the number of states and introduced
additional states before and after the disease progression states. In modeling HCV,
for example, state “Healthy” represents uninfected, states “F0”-“F4” represent the
METAVIR states, and the final state before death represents disease complications
including HCC and decompensation. Figure 12(b) shows a disease progression with
state dependent transition probabilities.
We are interested in comparing the model shown in Figure 12(a) with the model
shown in Figure 12(b). When the final state is “Death” then the direct transitions to
it (from states “Healthy - “N” ) represent death from causes other than the disease
being modeled. It is worth noting that the final state need not be “Death.” When
the final state represents a diseased state (perhaps a non-fatal disease), the direct
transitions to it represent the probability of acquiring the disease for reasons other
than those captured by the model’s states. In the case of time-dependent transition
probabilities, we are interested in comparing the model in Figures 11(b) and 11(a)
where we also assume that the “death” states feeds back into state 1 as it would in a
Monte Carlo simulation. Similarly, “Death” need not be considered the final state.
The remainder of the chapter is organized as follows. We first derive at stationary
distributions for models where the progression changes with state or with time. Then
we use the stationary distribution to arrive at conditions for bias. We then discuss
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factors that affect the degree of the bias. We apply the results to HCV, AD, and lung
cancer using medical data. Finally, we discuss the implications of the results when
Markov models of disease progression are used in studies of cost-benefit analysis,
forecasting future prevalence, and estimating future disease burden.
5.4 Stationary Distributions
5.4.1 State dependent transition probabilities
In this section we solve for the stationary distributions for the various models we are
considering. The stationary distribution of a Markov chain describes the steady state
behavior of the Markov chain, which allows us to draw conclusions about Markov
models in the long term. The stationary distribution of a Markov chain does not
depend on the initial state of the chain. In the case of modeling diseases, this means
that we do not need to assume an initial health state in our model; the results derived
from the stationary distribution will hold regardless of the initial health state or initial
distribution of health states (in the case of modeling populations). We will use the
stationary distributions derived in this section in our analysis of model bias in Section
5.5
The Markov models in Figure 12 are irreducible aperiodic Markov chains where all
of the states are positive recurrent (i.e., they are ergodic). If we add a direct path from
“death” to state 1 in the models in Figure 11 (as would be the case in Monte Carlo
simulations), then they are also ergodic. By Theorem 4.3.3 in Ross [104], there exists a
unique stationary distribution π for each of those ergodic Markov chains.. Moreover,
by Theorem 4.3.1 of Ross, the expected return time to state i (once the state is
entered) is given by 1
πi
. The death state is included for illustrative purposes and the
time spent in it is always one time period. Keeping the death state in the model
implies that 1
πDeath
− 1 represents the expected time from state “Healthy” to state
“Death”. It should be clear that solving the stationary distribution of the Markov
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Figure 13: Generalized Markov model of disease progression with state dependent
transition probabilities
chain in Figure 12(b) is equivalent to solving the stationary distribution of Figure
13, only differing in the labels given to the transition probabilities. Without loss of
generality, we use the Markov chain in Figure 13 in our analysis for the remainder
of this chapter. That is, the results throughout this chapter assume the comparison
of Figure 13 to the corresponding single probability transition Markov chain (i.e.,
where ai = x ∀ i). We subsequently prove, however, that all of our results remain
true in the more general case of comparing Figures 12(a) and 12(b), even when we
add additional states before state 1 and after state N (as long as they do not directly
communicate with any of the states 1 − N as shown in the Figures).
We begin with Figure 13 where d = 0 (i.e., there are no direct transitions to the
final state). In this case the analysis is simple. Solving
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1 − a1 a1 0 0 · · · 0
0 1 − a2 a2 0 · · · 0
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The proof of the solution to Equation 16 is a special case (where d = 0) of Proposition
1, which is proved in the Appendix. In the case that ai = x ∀ i, then πN = 11+ N
x
.
Next we consider Figure 13 where d > 0 (i.e., there are direct transitions to the
final state). In this case the analysis is more complicated. Solving
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1 − a1 − d a1 0 0 · · · d
0 1 − a2 − d a2 0 · · · d
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for π gives us the stationary distribution.
Proposition 1. The stationary distribution to the Markov chain in Figure 13 (i.e.,
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The proof of Proposition 1 is in the Appendix. Consequently, the expected time












It should be clear that if we consider the case where the ai = x ∀ i as it is in the













5.4.2 Time dependent transition probabilities
Next we solve for the stationary distribution to the Markov chain in Figure 11(b). In
this case, we must solve
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0 1 − a1 − d 0 0 · · · a1 d1
0 0 1 − a2 − d 0 · · · a2 d2
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Proposition 2. The stationary distribution to the Markov chain in Figure 11(b) (i.e.,













(1 − ai − di)
. (23)
The proof of Proposition 2 is in the Appendix. Consequently, the expected time










(1 − ai − di). (24)
Figure 11(a) is a special case (N = 3) of Figure 12(b). Consequently, we can use
the corresponding development to arrive at the expected time from state 1 to Death
as
Ex =
x + d + D
(x + d)(d + D)
. (25)
It should also be clear that if we consider the case where the ai = x ∀ i where the










(1 − x − di). (26)
5.5 Analysis of Bias
In this section, we analyze bias in the models described above. In our analysis, we
take the model with state/time dependent transition probabilities to be the status
quo, and define bias as the change in the expected time it takes to reach the final
state from the initial state when using constant transition probabilities (in place of
the state/time dependent transition probabilities). The proofs of the theorems below
are in the Appendix to this chapter.
5.5.1 Conditions for the existence of model bias
5.5.1.1 State dependent transition probabilities
For the special case where there are no direct transitions to the final state (i.e., d = 0)
in the model in Figure 13, it follows from Equation 17 that the bias, Ba,x, resulting
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from the use of a single probability transition, x, instead of the state dependent
probability transitions ai, is equal to











The model with the single transition probabilities overestimates (underestimates)




which is the har-
monic mean of the a′is.
We turn our attention to the case when there are direct transitions to the final state
(i.e., d > 0), which represent death from natural causes when the final state represents
death (or an alternative means of obtaining disease when the final state represents
a particular disease state). In this case, the bias condition is more complicated. We
are interested in comparing the models in Figures 12(a) and 12(b) to analyze the
consequences of using a single transition probability. With the framework introduced
in the previous section, we can arrive at sufficient conditions for bias.
We start by subtracting Equation 21 from 20 to arrive at the expression for differ-
ence in the expected time from state 0 to N when using a single transition probability
versus allowing the transition probabilities to vary by state, which gives us the fol-
lowing Theorem.
Theorem 3. For a disease progression of the type in Figure 13, the bias resulting
from the use of a single transition probability (i.e., ai = x ∀ i) versus allowing the






















where we measure bias by the difference in expected time from state 0 to state N.
Theorem 3 indicates the magnitude and direction of the bias. When x is calibrated
such that the expression in 27 is zero, then there is no bias. That is, the expected time
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from state 0 to state N is the same when using the state dependent probabilities or
that particular value of x. Using any other value for x results in bias in the direction
indicated by Theorem 3. Next, we describe sufficient conditions on the value of x for
the presence of bias.
Theorem 4. For a disease progression of the type in Figures 12(a) and 12(b), when
x is less than or equal to the harmonic mean of the a′is, and the a
′
is do not all
equal x, then the model with aggregated transition probabilities (Figure 12(a)) strictly
underestimates disease progression when compared to the model with state dependent
transition probabilities (Figure 12(b)).
The proof is in the Appendix. Theorem 4 states that the expected time from state
0 to N is larger when the harmonic mean of the state dependent transition proba-
bilities is used as a constant transition probability than when the state dependent
transition probabilities themselves are used. That is, model bias is strictly negative.
The result holds for any value less or equal to than the harmonic mean as well. It
follows from Theorem 4 that when a value smaller than the harmonic mean for x is
used, as the value of x decreases the degree of underestimation (i.e., bias) increases.
This is true since as x decreases, the time from state 0 to N increases, which is appar-
ent by examining Figure 13. The importance of Theorem 4 is that it shows that when
modeling a disease whose progression is not constant, using the harmonic mean of
the state dependent transition probabilities (instead of the state dependent transition
probabilities themselves) will cause the modeler to underestimate the progression of
the disease. When using a value smaller than the harmonic mean, the modeler will
increasingly underestimate the progression of the disease.
Corollary 1. Consider a disease progression of the type in Figures 12(a) and 12(b)
where the a′is are increasing. When x is computed using the indirect method, the model
with aggregated transition probabilities (Figure 12(a)) strictly underestimates disease
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progression when compared to the model with state dependent transition probabilities
(Figure 12(b)).
Corollary 1 is a special case of Theorem 4. It is important to note than when
using the indirect method as described in section 5.2, the modeler can average the
computed indirect value of many patients by taking the arithmetic mean of the in-
direct values, or more correctly, by taking the harmonic mean of the indirect values.
The choice of which mean to use is left to the modeler, however, the harmonic mean
is more appropriate when averaging rates. When averaging the expected times be-
tween states, the arithmetic mean is more appropriate. Indeed, the harmonic mean
of the progression rates (indirect values) is equivalent to the arithmetic mean of the
expected times between states. The proof of Corollary 1 in the Appendix discusses
the use of the arithmetic and harmonic means further. In Corollary 1, we assume
x is computed by taking the harmonic mean of the indirect values of many patients
(or equivalently, the arithmetic mean of the expected times between states). Corol-
lary 2 discusses the case where we use the arithmetic mean of the indirect values.
The importance of Corollary 1 is that it suggests that studies that use the indirect
method (the most common method of computing constant transition probabilities)
due to lack of disease data are underestimating the disease progression for diseases
such as HCV and AD that are believed to have increasing progression rates (i.e., the
sick get sicker faster).
Note that the converses of Theorem 4 and Corollary 1 do not follow, which can be
seen by a number of counter examples. We can, however, arrive at a result for model
bias in the opposite direction (overestimation) using the development in the proof of
Theorem 4.
Theorem 5. For a disease progression of the type in Figures 12(a) and 12(b), when
x is greater than or equal to the geometric (or arithmetic) mean of the a′is, and the
a′is do not all equal x, then the model with aggregated transition probabilities (Figure
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12(a)) strictly overestimates disease progression when compared to the model with
state dependent transition probabilities (Figure 12(b)).
The proof is in the Appendix. Theorem 5 states that the expected time from state
0 to N is smaller when the geometric mean of the state dependent transition prob-
abilities is used as a constant transition probability than when the state dependent
transition probabilities themselves are used. That is, model bias is strictly positive.
The result holds for any value greater than or equal to the geometric mean, including
the arithmetic mean. It follows from Theorem 5 that when a value larger than the
geometric mean for x is used (e.g., the arithmetic mean), as the value of x increases
the degree of overestimation (i.e., bias) increases. This is true since as x increases,
the time from state 0 to N decreases. The significance of Theorem 5 is that when
modeling a disease whose progression is not constant, using the geometric mean of
the state dependent transition probabilities (instead of the state dependent transi-
tion probabilities themselves) will cause the modeler to overestimate the progression
of the disease. When using a value larger than the geometric mean, the modeler will
increasingly overestimate the progression of the disease.
Corollary 2. Consider a disease progression of the type in Figures 12(a) and 12(b)
where the a′is are decreasing. When x equals the arithmetic mean of the computed indi-
rect values for each patient, the model with aggregated transition probabilities (Figure
12(a)) strictly underestimates disease progression when compared to the model with
state dependent transition probabilities (Figure 12(b)).
Corollary 22 is a special case of Theorem 5. Contrary to Corollary 1, we assume
x is computed by taking the arithmetic mean of the computed indirect values of the
patients. The importance of Corollary 2 is that it suggests that studies that use the
indirect method in this way are overestimating the disease progression for diseases
that have decreasing progression.
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5.5.1.2 Time dependent transition probabilities
Next, we consider Markov models with time dependent transition probabilities. Sub-
tracting Equation 26 from 24 gives us the expression for the difference in the expected
time from state 1 to state to Death when using a single transition probability ver-
sus allowing the transition probabilities to vary over time. Solving for x gives us a
condition for bias, which we formulate as our next theorem.
Theorem 6. A Markov model without time varying transition probabilities of the
type in Figure 11(a) overestimates (underestimates) the expected time to death when





where Ea is defined above and γ =
1
d+D
Theorem 6 indicates that when x equals the right hand side of inequality 28 the
bias is zero. That is, the expected time from state 1 to death is the same when using
the time dependent transition probabilities or that particular value of x. Using any
other value for x will result in bias in the direction indicated by Theorem 6.
The sufficiency theorems that are true for the state dependent transition probabil-
ities model are not true for the time dependent transition probabilities model. They
can be shown to be false by simple numerical counter examples, which we show in
Section 5.6
5.5.2 Factors that affect the degree of model bias
Thus far we have compared models where the transition probabilities are allowed
to vary between states with models that use a single aggregate transition probabil-
ity between several states. In this section, we consider intermediate levels of data
aggregation. That is, instead of considering only the use of a single transition proba-
































Figure 14: Markov models of disease with different degrees of aggregation
is formed by taking some mean of a1 and a2 only. By comparing the three models in
Figure 14 we will be able to analyze the effect of the degree of data aggregation on
model bias. The degree of data aggregation is increasing as we switch from using the
a′is to using the b
′
is to using c as the transition probabilities for the Markov chain.
Theorem 7. When using any value greater than or equal to the geometric mean
(e.g., the arithmetic mean) of the transition probabilities in Figure 14, the models
with aggregated transition probabilities increasingly overestimate disease progression
as the degree of aggregation increases.
It is worth recalling that the value computed using the indirect method (and av-
eraging over many patients using the arithmetic mean) is greater than the arithmetic
mean of the a′is for diseases that have decreasing progression. For this computed
value, Theorem 7 applies for diseases that have decreasing progression.
88
Theorem 8. When using any value less than or equal to the harmonic mean of the
transition probabilities in Figure 14, the models with aggregated transition probabilities
increasingly underestimate disease progression as the degree of aggregation increases.
Recall that the value computed using the indirect method (and averaging over
many patients using the harmonic mean) is less than the harmonic mean of the a′is
for diseases that have decreasing progression. For this computed value, Theorem 7
applies for diseases that have decreasing progression. Theorems 7 and 8 state that
bias increases as the degree of data aggregation increases, and that the increased bias
is in the same direction as determined by Theorems 4 and 5. They are both proven
in the Appendix to this Chapter.
5.6 Bias in Models of Hepatitis C, Alzheimer’s Disease and
Lung Cancer
In this section we use medical data to calculate the bias in models of three diseases
introduced in Section 5.2. We start with models whose transition probabilities vary
by state and use HCV and AD as examples. Disease progressions of HCV and AD
were introduced in Section 5.2, and HCV with its corresponding disease model was
extensively discussed in Chapter 4. We also use HCV, AD and lung cancer to show
bias in models with time dependent transitions.
5.6.1 Bias in diseases with state dependent transition probabilities: Hep-
atitis C and Alzheimer’s Disease
In this section we use HCV and AD as examples for bias in Markov models of diseases
with state dependent transition probabilities when we aggregate the data and assume
constant transition probabilities. In the case of HCV, the progression through the
METAVIR states has been shown to vary by liver disease severity [71, 145]. In this
case, model states represent METAVIR states where the transitions between states
vary as shown in Table 15, where ai is the transition probability of going from state i to
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state i+1. We consider several different data sets for the same disease. The transition
probability labeled “indirect” corresponds to the single transition probability obtained
using the indirect method introduced in Section 5.2 where a constant linear disease
progression is assumed. The indirect value reported in each case was obtained by the
same corresponding study that computed the a′is in order to ensure that we do not
introduce ab extra bias by using parameters derived from different data sets.
In the case of AD, the progression has also been shown to vary significantly by
severity [119, 121]. The Markov model states in this case represent the grouped
MMSE scores (see section 5.2 for an introduction) of an individual with AD, where
the probability of transitioning between states varies according to Table 15.
There are very few studies that compute a′is for HCV, while several studies have
computed them for AD. We chose studies that arrived at very different values for the
a′is (due to studying different populations) so that we can test for bias under very
different scenarios. For example, the a′is for Yi 1 pertain to 1138 chronic HCV patients
in liver clinics who have disproportionately faster progression than those in Yi 2, which
is made up of previously healthy women infected by exposure to contaminated anti-D
immune globulin who were then screened for HCV. The data from Matsumura was
obtained from Japanese patients infected with HCV that have chronic liver disease.
Similarly, while the Stern and Suh data sets are on different scales, they also report
very different progressions based on the populations considered.
Table 15: Parameter values for transition probabilities
HCV AD
Yi 1 Yi 2 Matsumura Stern Suh
a1 0.169 0.042 0.049 0.176 0.097
a2 0.118 0.045 0.217 0.588 0.070
a3 0.225 0.097 0.556 0.765 0.053
a4 0.207 0.070 0.294 0.412
indirect 0.150 0.045 0.120 0.562 0.077
Source Yi [145] Yi [145] Matsumura [71] Stern [119] Suh [121]
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Table 16 displays the results for comparing the use of a single transition probability
versus using the a′is for HCV and AD. The expected time to death is displayed using
the indirect value as well as the harmonic (harm), geometric (geo) and arithmetic
(arith) means, respectively. We use the death rates from the CDC [23]. For each
data set, we compute the percent change (%△) relative to using the a′is. Note that
the indirect method results in greater bias in all cases but one (the arithmetic mean
using data from Matsumura for HCV). In all cases, the harmonic mean results in less
bias than any other single transition probability considered.
The arithmetic mean consistently results in the largest bias among the three
means. We also compare the use of the a′is to the use of two probability transition
values as in Figure 14 where we use the three different means. Using two probability
transition values represents a lower degree of data aggregation than using only one.
The direction of the bias remains constant, while the magnitude decreases as pre-
dicted by Theorems 7 and 8. In most cases, the bias decreases significantly between
using a single transition probability versus two. It is also interesting that for the data
sets where the a′is vary a great deal, the bias is much larger.
5.6.2 Bias in diseases with time/age dependent transition probabilities:
Hepatitis C and Alzheimer’s Disease and Lung Cancer
In this section we use HCV, AD and lung cancer as examples for bias in Markov
models of diseases with transition probabilities that vary by time/age. In the case of
HCV, the progression through the METAVIR states have been shown to vary by age
[57, 96, 123]. The Markov model states in this case represent ages of an individual
(while infected with HCV), where the transition to the disease state (cirrhosis) vary
by age as shown in Table 17. In the case of AD, the risk of acquiring AD has been
shown to increase with age [93]. The Markov model states in this case represent the
ages of an individual without AD, where the probability of transitioning to the disease
state (i.e., acquiring AD) varies by age according to Table 18. In the case of lung
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Table 16: Results for HCV and AD with state dependent transition probabilities
for multiple degrees of data aggregation






s indirect harm geo arith harm geo arith
Yi 1 18.57 20.47 18.61 18.13 17.71 18.58 18.44 18.29
%△ 10.22% 0.23% -2.36% -4.66% 0.08% -0.72% -1.51%
Yi 2 39.16 44.06 39.38 38.21 36.96 39.18 39.07 38.95
%△ 12.51% 0.57% -2.42% -5.62% 0.05% -0.24% -0.53%
Mat 21.72 24.27 22.54 15.93 12.18 22.16 18.80 15.90
%△ 11.71% 3.73% -26.69% -43.91% 1.99% -13.46% -26.83%
AD
Stern 9.63 6.43 9.70 8.34 7.37 9.68 8.62 7.69
%△ -33.25% 0.69% -13.46% -23.44% 0.49% -10.49% -20.14%
Suh 28.19 26.37 28.29 27.74 27.19 28.21 28.07 27.93
%△ -6.47% 0.34% -1.61% -3.56% 0.08% -0.43% -0.93%
cancer, we use the model in Figure 11(b) where each state represents the number of
years an individual has smoked cigarettes. In this case we use the function
p(n) = 1.845 × 10−10n4.5 (29)
as the probability of transitioning to lung cancer after smoking for n years, which
is obtained from Scherrer’s study [109]. The data used by Scherrer to arrive at this
function was originally based on Doll and Peto [41] for individuals who smoke 20
cigarettes per day beginning at age 16.
Table 17: Liver Fibrosis estimates for HCV model. Source [57]








Table 18: Incidence of AD. Source [93]









Table 19 displays the results for comparing the use of a single transition probability
versus using the a′is for HCV and AD. For HCV, we assume the individual acquires
HCV at age 20 and we compute the expected time until death from age 20 onwards
using the death rates from the CDC from Chapter 4. For AD, we consider the
incidence starting at age 60 (since the incidence before age 60 is very small) and
compute the expected time to death from age 60 onwards using the same death rates.
We compare the use of the harmonic, geometric and arithmetic means. Note that
the results serve as counterexamples to show that Theorems 4 and 5 do not hold for
models with time dependent transition probabilities as they do for models with state
dependent transition probabilities. The harmonic mean results in smaller bias for
both cases, however this is not necessarily always the case.
Table 20 displays the results for comparing the use of a single transition probability
versus using the a′is for lung cancer. We assume the individual begins smoking 20
cigarettes per day starting at age 15 and use same death rates from the CDC as in
the previous table. We compare the use of the harmonic, geometric and arithmetic
means. Note that the harmonic mean does not always result in smaller bias. We also
show the results for different levels of data aggregation. We compare the use of the
a′is to the use of two, three and four probability transition values in the way described
in Figure 14 where we use the three different means. Note that the direction of the
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Table 19: Results for HCV and AD with time dependent transition probabilities




s arithmetic geometric harmonic
Expected time
to death from 33.91 25.16 28.89 32.32
age 20
%△ -25.79% -14.82% -4.70%
AD incidence starting at age 60
Expected time
to death from 20.75 16.52 19.47 21.35
age 60
%△ -20.35% -6.14% 2.89%
bias does not always remain constant. However, the bias does decrease significantly
when decreasing the degree of data aggregation. The results in Tables 19 and 20 are
not sensitive to the death rates since they are driven by the a′is.
Table 20: Results for Lung Cancer with time dependent transition probabilities for
multiple degrees of data aggregation (smoking 20 cigarettes/day since 15 years old)





s arith geo harm arith geo harm
Expected time
to death from 59.98 45.64 61.47 62.97 57.67 61.46 59.87
age 15
%△ -23.92% 2.47% 4.97% -3.86% 2.46% -0.19%
3 transition 4 transition
probabilities probabilities
arith geo harm arith geo harm
Expected time
to death from 59.30 59.74 60.12 59.82 59.92 60.02
age 15
%△ -1.13% -0.40% 0.23% -0.28% -0.10% 0.07%
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5.7 Discussion
The results in this Chapter suggest that efforts should be made to obtain/use disease
data that allow for estimating transition probabilities that are state and/or time
dependent in order to minimize model bias. When constant transition probabilities
must be used due to limited data, or for analytical tractability, caution must be
exercised when choosing the value for the transition probability in order to reduce
the affect of bias. The Theorems in Section 5.5 give us simple sufficient conditions to
test for the presence of bias in two different Markov models of diseases. The disease
models can include state dependent transition probabilities or time/age dependent
probabilities. For the case of state dependent transition probabilities, we also show
analytically that the bias increases as the degree of data aggregation increases, and
that the increased bias is in the same direction as determined by Theorems 4 and 5.
The results in Section 5.6 show that the bias can be significant in many cases
when models use constant transition probabilities. Using the indirect method, which
is a common practice in each of the diseases discussed, resulted in larger bias than
any of the three means considered in all cases except for one. Additionally, the bias
increases dramatically when the degree of data aggregation increases.
The case where insufficient disease data causes the modeler to use the indirect
method of obtaining a constant transition probability is of particular interest since
it is such a common occurrence. We showed that the transition probability derived
using the indirect method is less than harmonic mean of the state dependent transition
probabilities when they are increasing. This result is important because it means that
the use of the indirect method for diseases with increasing progression rates leads to
an underestimation of disease progression. We also showed that when the arithmetic
mean is used to average the indirect values of many patients, the disease progression
is overestimated for diseases that have decreasing progression rates.
It is noteworthy that many studies that produce estimates for the state dependent
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transition probabilities of diseases with increasing progression rates don’t always ar-
rive at strictly increasing transition probabilities. Results often include progression
rates that increases until the final states where progression then slows down, such as
those used in section 5.6. In light of the progressive nature of the diseases studied,
the authors typically attribute the observed slower progression in the final states due
to ceiling effects of the scoring system (e.g. MMSE), and not to the nature of the
disease itself, such as in Park, et al, [85] and Aguero-Torres et al, [1]. Nevertheless,
we used the transition rates as reported in the literature and found the bias to be
significant when using the indirect method.
The implication of our results is that many of the studies that assume constant
transition probabilities are arriving at conclusions based on biased models, bias po-
tentially as large as the examples in Section 5.6. Analyses that use Markov models of
disease progression that ignore the state/time dependency of the probability transi-
tions to determine the cost-effective of medical interventions such as pharmaceutical
drugs, therapies or screening programs may be significantly biased towards or away
from cost-effectiveness depending on the type of aggregation used. A cost-effectiveness
study of HCV, for example, that assumes a constant disease progression and uses the
harmonic mean (or any smaller value) for the disease progression could potentially
determine a cost-effective medical intervention to not be cost-effective because the
disease progression was underestimated.
Similarly, when estimating future prevalence, if a disease model overestimates
(underestimates) the progression to death, ceteris paribus, then future prevalence is
underestimated (overestimated). For many diseases, the health states become costlier
and associated with lower quality of life as the disease progresses, as is the case with
HCV, AD and lung cancer. In these cases, it is clear that if we calibrate the models
such that they have the same expected time from the first state to the final state,
when the disease progression increases (decreases) in time/state, the Markov models
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that use a single probability transition overestimate (underestimate) the time spent
in the later states. This can be important since the later states can be significantly
costlier than the earlier states in the disease progression causing the disease burden
forecast to be biased.
Finally, we close with a discussion of an important aspect of Markov models of
disease progression that causes bias in addition to the bias caused by the issues stud-
ied herein. The additional bias introduced into Markov models of disease progression
is due to the fact that transition probability estimates are typically inherently under-
estimated. This is true because when a patient is determined to be in a particular
health state at some point in time (by a liver biopsy, for example), there is no way of
knowing how long the patient was in that state. Consequently, the estimate for the
rate of progression is commonly made assuming the patient entered that diagnosed
state in the time period of the diagnosis. For this reason, estimates of the disease
progression are typically lower bounds. As a result, the bias introduced by the use
of a single transition probability (instead of state/time dependent probabilities) can
be either increased or decreased by this measurement effect. In the case that the use
of a single transition probability causes an underestimation of disease progression,
the bias due to measurement will cause the disease progression to be underestimated
even more so than the results in Section 5.6 suggest.
5.8 Appendix
For the proofs in this appendix, it is helpful to first introduce some mathematical
tools that we will use in our analysis of model bias. We start by introducing elemen-
tary symmetric polynomials, which are special cases of symmetric polynomials. The
elementary symmetric polynomial of degree m in n variables (where m ≤ n) is the
sum of all distinct products of degree m of the n variables. In other words, we form
all m-tuples of the n variables and add them up.
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Definition 1. The elementary symmetric polynomial of degree m in n variables is
defined as




For example, when n = 3, the elementary symmetric polynomials are
e3,0(x1, x2, x3) = 1
e3,1(x1, x2, x3) = x1 + x2 + x3
e3,2(x1, x2, x3) = x1x2 + x1x3 + x2x3
e3,3(x1, x2, x3) = x1x2x3.
Definition 2. An alternative definition for en,m(x1, x2, · · ·xn) is that of the coefficient




It should be clear that the en,m
en,n
= en,n−m where en,n−m are the elementary symmet-




, · · · 1
xn
. Next, we use the elementary symmetric polynomials
in the following definition.







Sn,m is the elementary symmetric polynomial of degree m in n variables divided
by the number of terms in this polynomial. We use Sn,m extensively in the proofs
below to simplify notation. Additionally, we use a relationship between the Sn,i called
MacLaurin’s inequality.
MacLaurin’s inequality states that
Sn,1 ≥ (Sn,1)1/2 ≥ (Sn,2)1/3 ≥ · · · ≥ (Sn,n)1/n
with equality if and only if all of the xi values are equal. We use MacLaurin’s in-
equality in the proofs for Theorems 4 and 5.
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Lastly, we introduce the following Lemma, which we use to reformulate the expres-
sion for the stationary distribution of Markov models with state dependent transition

























which we prove below.
Proof of Proposition 1
Multiplying the right hand side of Equation 18 gives us
π1 = π1(1 − a1 − d) + πN
π2 = π1a1 + π2(1 − a2 − d)
π3 = π2a2 + π3(1 − a3 − d)
...
...
πN−1 = πN−2aN−2 + πN−1(1 − aN−1 − d)
πN = πN−1aN−1 + d(π1 + π2 + · · ·+ πN−1) (31)
which can be written as
π1a1 = π2(a2 + d)
π2a2 = π3(a3 + d)
π3a3 = π4(a4 + d)
...
...
πN−1aN−1 = πN (1 + d) − d
πN = π1(a1 + d). (32)
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We know that for a stationary distribution
π1 + π2 + π3 + · · ·+ πN = 1 (33)






(a1 + d)(a2 + d)
+
πNa1a2
(a1 + d)(a2 + d)(a3 + d)
+ · · ·+ πNa1a2 · · ·an
(a1 + d)(a2 + d)(a3 + d) · · · (aN−1)
+ πN = 1 (34)
which can be rewritten as Equation 19. 2
Proof of Proposition 2
Multiplying the right hand side of Equation 22 gives us
π1 = πD
π2 = π1(1 − a1 − d) = πD(1 − a1 − d)
π3 = π2(1 − a2 − d) = πD(1 − a1 − d)(1 − a2 − d)
...
...
πN = πN−1(1 − aN−1 − d) = πD(1 − a1 − d)(1 − a2 − d) · · · (1 − aN−1 − d)
πC = π1a1 + π2a2 + · · ·+ πNaN + πC(1 − D)
πD = π1d1 + π2d2 + · · ·+ πNdN + πC(D).
Since we know that Equation 33 must hold for a stationary distribution, rewriting
Equation 33 in terms of πD using the above equations gives us the desired expression
for πD and we are done. 2
Proof of Lemma 2
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Let us define the following string of identities
∏
1≤i≤N
(ai + d) = d
∏
2≤i≤N






(ai + d) = d
∏
3≤i≤N






(ai + d) = d
∏
4≤i≤N








(ai + d) = d
∏
N−1≤i≤N






(ai + d) = d
∏
N≤i≤N




Substituting from the bottom up recursively we have
∏
1≤i≤N
(ai + d) = d
∏
2≤i≤N
(ai + d) + da1
∏
3≤i≤N




+ · · ·+ da1a2 · · ·aN−2(aN + d) + da1a2 · · ·aN−1. (35)
















(ai + d) + a1
∏
3≤i≤N
(ai + d) + a1a2
∏
4≤i≤N









(ai + d) + a1
∏
3≤i≤N
(ai + d) + a1a2
∏
4≤i≤N
(ai + d) + · · · + a1a2 · · ·aN−1.
From Equation 35 we have
∏
1≤i≤N




and we are done. 2
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Proof of Theorem 4
We start by analyzing the Markov disease model in Figure 13 and comparing it to
the case where ai = x ∀ i. Then we extend the result to be true in the more general
case of Figures 12(a) and 12(b). When x is less than or equal to the harmonic mean






From Equation 21, for the disease progression in Figure 13, we know that the expected















































N−3 + · · ·+ eN,N−1d
dN + eN,1dN−1 + eN,2dN−2 + · · ·+ eN,N−1d + eN,N
.





N−3 + · · ·+ eN,1
eN,NdN + eN,N−1dN−1 + eN,N−2dN−2 + · · ·+ eN,1d + 1
(37)









Note that since the denominator can be written by multiplying the numerator by








N−3 + · · ·+ eN,1.
We can arrive at a similar expression for the expected time from state 0 to state
N in the model with aggregated transition probabilities where we have x′s instead of
a′s. Using the same procedure as above we get that the expected time from state 0








































Similarly, since the denominator can be written by multiplying the numerator by






















dN−3 + · · ·+ N
x
.
We would like to compare the expected time from state 0 to state N using a′s







then it follows that the model in which x′s are used underestimates the disease pro-
gression since the expected time from state 0 to state N is longer. Since the inequality




























































Next we must show that the terms labeled a, b, c, · · · are strictly less than the





























= SN,1 and by Maclaurin’s inequality SN,1 > (SN,m)
1
m for
all m whenever the ai are not all equal, then inequality 41 is always true. The proof
that the result remains true in the general case of the model in Figure 12(b) is below.
2
Proof of Corollary 1
Given Theorem 4, we need only to show that when the a′is are increasing, the
value computed using the indirect method is less than the harmonic mean of the
a′is. The indirect method is computed without taking into account death from other
causes (i.e., when d = 0). It is a well known property of the harmonic mean that it
equals the arithmetic mean of the reciprocals. Indeed, the harmonic mean is most
useful when averaging rates. Since ai represents the transition probability from state
i to i+1, when d = 0 the expected time from state i to i+1 is 1
ai
:= ti. Consequently,
the harmonic mean of the a′is is equal to the arithmetic mean of the t
′
is. When the
a′is are increasing (i.e., t
′



















(t1 + t2 + · · · + tN)
=
N
(1/a1 + 1/a2 + · · · 1/aN)
(43)
which is equal to the harmonic mean of the a′is, and we are done. 2
Proof of Theorem 5
As in the proof of the previous theorem, we start by analyzing the Markov disease
model in Figure 13 and compare it to the case where ai = x ∀ i. We start with
Equations 37 and 38 from the proof of Theorem 4. In this case, however, we want to







which is true when B < A. In this case, we must show that the expression on the
left hand side of Equation 40 is greater than the expression on right hand side of










which is the reciprocal of the geometric mean of the a′is. It remains to show that the
terms labeled b, c, · · · , d are strictly greater than the terms labeled b′, c′, · · · , d′ in






































m for all m whenever the ai are not all equal, then inequality 46 is always true.
Since the geometric mean is always less than or equal to the arithmetic mean, the
result holds for the arithmetic mean as well. The proof that the result remains true
in the general case of the model in Figure 12(b) is below. 2
Proof of Corollary 2
Given Theorem 5, we need only to show that when the a′is are decreasing, the
arithmetic mean of the indirect values of the patients is greater than the arithmetic
mean of the a′is. When the a
′
is are decreasing, the t
′
is are increasing, and we can see










+ · · · N

















(a1 + a2 + · · ·+ aN ), (48)
which is equal to the arithmetic mean of the a′is, and we are done. 2




























(a1 + d)(a2 + d)
+
a1a2
(a1 + d)(a2 + d)(a3 + d)
+ · · ·+ a1a2 · · ·an















We want to show that the inequality remains true when we add the transition prob-
abilities i, z, and D to the stationary distribution according to the Markov model in
Figure 12(b). By updating Equation 34 (where we derived the stationary distribu-






(i + d)(a1 + d)
+
ia1
(i + d)(a1 + d)(a2 + d)
+ · · ·+ ia1 · · ·anzD






(i + d)(x + d)
+
ix
(i + d)(x + d)2
+ · · ·+ ix
NzD
(i + d)(x + d)N−1(z + d)(D + d)
which is clearly true whenever inequality 49 is true. The result is also true for the
reverse inequality. 2
Proof of Theorem 7
To show that bias increases as the degree of aggregation increases, we must prove
that
Ea > Eb > Ex
when the a′is and b
′
is are not all equal to x, and b1 =
√
a1a2 and b2 =
√
a3a4. Ea > Ex
and Eb > Ex are true by Theorem 5 from the previous section. It remains to show
that Ea − Eb is strictly positive, which expands to
Ea − Eb = (50)
a1a2a3a4








a3a4 + a2da4 + a1a3a4 + a1da3 + a1da4 + d
2a3 + a2a3a4 (52)
+a2d
2 + a2a3d + a1a2a4 + a1a2a3 + a1d
















Since the fraction in line 51 is always positive, it suffices to show that lines 52 -
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53 are strictly positive. These lines can be rewritten as a polynomial in d as
d2 (−2√a1a2 + a1 + a2 + a3 + a4 − 2
√
a3a4)









a1a2 + a1a2a4 + a1a3a4 + a2a3a4 + a1a2a3).
Next we show that each coefficient of the powers of d is strictly positive. Rewriting































The above inequalities are true by repeatedly applying the inequality of the arith-






whenever a1 6= a2 (which is a special case of the Maclaurin inequality where n=2). It
should be clear that the result holds for any mean greater than or equal to geometric
mean. In the same way that Theorems 4 and 5 were shown to still be valid in the
more general setting where we include additional states before and after the disease
progression, this theorem is also true in the more general setting. The proof is omitted
since it follows the same steps. 2
Proof of Theorem 8
We omit the proof since it very closely follows that of Theorem 7, where instead





whenever a1 6= a2 and a1, a2 > 0 which can be seen to be true since (a1 + a2)2 > 0. It
should be clear that the result holds for any mean less than or equal to the harmonic
mean. In the same way that Theorems 4 and 5 were shown to still be valid in the
more general setting where we include additional states before and after the disease
progression, this theorem is also true in the more general setting. The proof is omitted
since it follows the same steps. 2
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CHAPTER VI
CONCLUSIONS AND FUTURE RESEARCH
DIRECTIONS
This thesis introduced several issues regarding the study of diseases. In Chapter
2, we studied a specific question in HIV policy regarding the proposed closure of
bathhouses as a control measure to reduce the spread of HIV among MSM. To answer
the question, we developed a Bernoulli process transmission model of a heterogeneous
population with multiple risk groups. We included the effect of co-infection with other
diseases, such as Syphilis, which increase the probability of transmission when present.
We showed that the HIV attack rate is concave as a function of the proportion of
the bathhouse patrons’ contacts with other bathhouse patrons. We used this fact to
draw conclusions on the effect of closing bathhouses under certain assumptions.
We populated the model of HIV transmission with data from a survey of four major
cities in the US and found that the impact on HIV incidence from the disproportionate
mixing of the population due to the presence of bathhouses is small compared to the
impact from changes in some key parameter values, such as condom usage. The effect
that closing bathhouses will have on these parameter values is not clear; however, the
result suggests that alternative interventions targeted at individuals in bathhouse
venues could have greater effects on the spread of HIV than closing bathhouses.
In Chapters 3 and 4, we built a mathematical model to examine the timing of
testing and treatment for diseases, particularly Hepatitis C. We studied the problem
with a dual approach. We developed Markov Decision Process model that arrives at
a dynamic testing policy for a disease model with a simplified state space (Chapter
3) and one in which we examine all possible testing policies for the full disease state
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space model via simulation (Chapter 4). The model allows for the awareness of a
disease to change behavior including the consumption of alcohol and transmission to
others.
We use medical data of Hepatitis C in both Chapters 3 and 4, and find that the
current policy recommendations of testing for Hepatitis C are too restrictive, and
that it is indeed cost-effective to test the overall population. We also demonstrate
the importance of including behavior changes in the model by comparing the results
to previous studies.
The topic in Chapter 3 has potential to motivate future research. In the future,
we plan to expand the dynamic model of testing for diseases to include a larger
state space. The analytical expressions become more cumbersome, but closed form
expressions can still be obtained. With an expanded model we will more accurately
represent diseases, and be able to model more complicated diseases. We intend to
apply both the dynamic and simulation models to other diseases where there is no
consensus regarding screening policies. Possible diseases include cancer and other
STD’s.
The Markov model used in the study of Hepatitis C in Chapters 3 and 4 motivated
the topic in Chapter 5 where we examine bias in Markov models of diseases, including
the one studied in Chapters 3 and 4. We consider two common types of diseases and
the associated Markov models commonly used to model them: ones in which the dis-
ease progression changes by severity of the disease, and ones in which the progression
of the disease changes in time or by age. We find sufficient conditions for bias to exist
in models with aggregated transition probabilities when compared to models with
state/time dependent transition probabilities. We also find that when aggregating
data to compute transition probabilities, the bias increases with the degree of data
aggregation.
We examine the bias in Markov models of Hepatitis C, Alzheimer’s disease and
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lung cancer using medical data and find that the bias is significant depending on the
method used to aggregate the data. The common method of acquiring a constant
probability transition, the indirect method, typically causes bias greater than that
of using the harmonic or geometric means. The key implication is that by not in-
corporating state/time dependent transition probabilities, studies that use Markov
models of diseases may be significantly overestimating or underestimating disease
progression, depending on the type of data aggregation used. This could potentially
result in incorrect recommendations in cost-effectiveness studies and incorrect future
prevalence and disease burden forecasts.
The topic in Chapter 5 also has potential for future study. We plan to generalize
the state space so that the disease progression may lead to two different final states
before death. This will be useful since, in the case of Hepatitis C for example, liver
disease can lead to decompensated cirrhosis and/or hepatocellular carcinoma, both
of which are fatal. We also intend to consider bias in other types of Markov disease
models, including ones with more complicated state spaces, or perhaps when the
transition probabilities depend on time and state.
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